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1. Introduction 
1.1 Alzheimer’s disease 
When Alois Alzheimer presented the case of his patient Auguste Deter at the 
Tuebingen meeting of the Southwest German Psychiatrists in 1906, he did not attract much 
attention or stimulate any discussion in the audience. The young doctor likely would not have 
believed that, 100 years later, the disease that now holds his name would be the most common 
cause of dementia and a source of critical medical and economical problems. At this meeting, 
Alzheimer presented Auguste Deter’s symptoms and reported the histopathological features 
that are now associated with Alzheimer disease (AD): neuron loss, extracellular amyloid 
plaques and intracellular neurofibrillary tangles (Dahm, 2006). 
 
1.1.1 Epidemiology 
According to the World Alzheimer Report 2010, there were 35.6 million people 
worldwide living with dementia in 2010 (World Alzheimer Report, 2010). This number will 
increase to 65.7 million by 2030 and 115.4 million by 2050. Around two-thirds of current 
patients live in low and middle-income countries, where the sharpest increase in numbers is 
set to occur. AD accounts for 50-60% of the dementia cases (Ferri et al., 2005). The number 
of people suffering from dementia in Germany is approximately 1.2 million; in which AD 
accounts for two thirds of cases (Deutsche Alzheimer Gesellschaft, 2010). In Lebanon, there 
is an estimated number of 30,000 AD cases and an estimate of 1.5 million cases in Arab 
countries (Alzheimer’s Association Lebanon, 2011).  
Life expectancy for patients with AD can vary from 3 to 10 years (Zanetti et al., 2009). 
According to the World Health Organization report 2011, AD and other forms of dementias 
represent the fourth highest cause of death in high-income countries, accounting for 4.1% of 
the total deaths. The total estimated worldwide costs of dementia were 604 billion US dollars 





1.1.2 Clinical features  
AD is a slowly progressive disorder manifested by many symptoms that affect 
memory in addition to other cognitive and behavioral abilities of the patients. Prior to the 
appearance of clinical symptoms, neurodegeneration starts and accumulates until it reaches a 
certain threshold, during which neuropsychological tests can reveal mild cognitive 
impairments (MCI) (Linn et al., 1995). MCI is defined by cognitive decline greater than what 
is expected for an individual's age and education level, but which does not interfere notably 
with daily life activities. At this stage, the differentiation between incipient AD, a reversible 
condition, normal aging or other forms of dementia is unreliable (Gauthier et al., 2006).  
The amnesic subtype of MCI exhibits a high risk of progression to AD and thus can be 
considered a predemential stage of the disease (Petersen, 2004). The predementia stage of the 
disease starts with impairments in episodic memory, which is represented by difficulties with 
recent memories. In addition, subtle effects on other cognitive functions start to appear; this 
may include planning, attention, flexibility, abstract thinking and verbal ability (Mega et al., 
1996; Forstl and Kurz, 1999). In the early stages of the disease, the deterioration in the recent 
form of the declarative memory continues, in addition to vocabulary shrinkage, spatial 
disorientation, depression and apraxia (Moore and Wyke, 1984; Burns et al., 1990; Locascio 
et al., 1995; Trobe et al., 1996). As the disease progresses, the patients require close 
supervision due to the loss of daily life skills, worsening of vocabulary, hallucinations and 
delusions, aggression, irritability and wandering (Mega et al., 1996; Forstl and Kurz, 1999). 
At the terminal stages of the disease, all forms of memory including early memories are 
usually severely impaired. Besides, patients may develop some motor impairments such as 
poor facial expression, rigidity, posture/gait and bradykinesia (Scarmeas et al., 2004). Some 
AD patients show epileptic seizures as well (Romanelli et al., 1990). 
 
1.2 Neuropathological hallmarks 
1.2.1 Amyloid plaques  
The amyloid plaques are spherical and complex protein accumulations with β-sheet 
structure. They can be divided into neuritic plaques and diffuse plaques (Yamaguchi et al., 
1988b; Small, 1998). Neuritic plaques represent one of the major hallmarks of AD. They 
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Fig. 2. Neurofibrillary 
tangles in AD. Anti–
phospho-tau antibody reveals 
hyperphosphorylated tau 
accumulation in neuronal cell 
bodies (large arrow). Adapted 
from (Holtzman et al., 2011) 
Fig 1. Amyloid plaques visualized by 
immunohistochemistry. A) A neuritic plaque with 
dystrophic neurites (small arrow). Adapted from 
(Holtzman et al., 2011). B) Diffuse plaques. Adapted 
from (Duyckaerts et al., 2009). 
consist of foci of extracellular amyloid beta 
(Aβ) peptides associated with axonal and 
dendritic enlargements that contain 
degenerated mitochondria, organelles and 
lysosomes (dystrophic neurites). Microglia 
frequently exist within and adjacent to the 
amyloid core, whereas astrocytes surround the 
plaque and send their processes towards it. A 
cross section of a neuritic plaque varies from 
10 to 120 μm in size and the densities of 
amyloid fibrils vary among plaques as well. In addition to Aβ, neuritic plaques in AD patients 
contain many other proteins such as Tau, amyloid precursor protein (APP) and ubiquitin (Su 
et al., 1998; Norfray and Provenzale, 2004)  
On the other hand, diffuse plaques vary in size from 50 μm to several hundred μm and 
consist of amorphous, non-fibrillar plaques of Aβ with little or no detectable neuritic 
dystrophy (Yamaguchi et al., 1988a) (Fig. 1). Therefore, they were suggested to represent 
precursors in neuritic plaque generation (Dickson, 1997). 
 
1.2.2 Neurofibrillary tangles  
In contrast to the extracellular amyloid plaques, neurofibrillary tangles (NFTs) consist 
of large non-membranous bundles of abnormal fibers present in 
the perikarya or in the apical dendrites (Fig. 2). Using electron 
microscopy, it was revealed in the early 1960’s that NFTs consist 
mostly of 10 nm filament pairs wound into paired helical filaments 
(PHFs) (Kidd, 1963). It took around three decades to confirm the 
composition of these PHFs to be hyperphosphorylated tau protein 
(Grundke-Iqbal et al., 1986; Lee et al., 1991). Tau protein is a 
member of the microtubule-associated proteins family (MAPs) 
that is encoded by a single gene on chromosome 17 containing 
16 exons (Neve et al., 1986). Alternative splicing of these exons 
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produce the six isoforms that are present in the human brain (Goedert et al., 1989). Tau is 
mainly expressed in neurons of the central nervous system (CNS) where it is primarily located 
in the axons and absent from the dendrites. It interacts with tubulin in order to promote its 
assembly into microtubules and to stabilize microtubules; therefore, it is important for 
stabilizing axons (Hirokawa et al., 1996). However, hyperphosphorylation of tau leads to its 
dissociation from microtubules and its subsequent aggregation into PHFs (Alonso et al., 
2001). Several kinases have been suggested to be involved in phosphorylating tau at various 
sites such as glycogen synthase kinase 3 (GSK-3) (Mandelkow et al., 1992), cyclin-dependent 
kinase 5 (CDK-5) (Baumann et al., 1993) and mitogen-activated protein kinase (MAPK) 
(Drewes et al., 1992).  
Although NFTs are widely considered to be downstream of amyloid pathology, they 
represent a better correlate with clinical and cognitive stages in AD patients in comparison to 
the neuritic plaques, and they are thus widely used for postmortem staging of AD (Braak and 
Braak, 1991). 
 
1.2.3 Neuron loss and brain atrophy 
In addition to amyloid plaques and NFTs, neuronal loss in some cortical and 
subcortical regions represents a main pathological feature of the disease. During the 
progression of the disease, the persistent neuron loss leads to atrophy in various brain regions 
such as the hippocampus, entorhinal cortex, and 
nucleus basalis of Meynert. Using unbiased 
stereological techniques, it was shown that significant 
neuron loss was detectable in the entorhinal cortex in 
early subtle cases of AD (Gomez-Isla et al., 1996). 
No neuron loss was reported in the hippocampus of 
preclinical AD cases, whereas significant neuronal 
loss was detected in the CA1, hilus and subiculum of 
AD cases (West et al., 2004). The nucleus basalis of 
Meynert is a major source of cholinergic innervations 
for the cerebral cortex and is one of the first brain 
Fig. 3. Brain atrophy in AD. Postmortem 
brain section from an AD case (left) 
compared with cognitively normal individual 
(right) reveals severe brain atrophy in AD. 
Adapted from (Holtzman et al., 2011). 
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regions discovered with profound neuron loss (Davies and Maloney, 1976; Cullen et al., 
1997). In addition, neuronal death has been reported in other brain regions such as the anterior 
olfactory bulb (ter Laak et al., 1994), amygdala (Vereecken et al., 1994), lower and medial 
parts of substantia nigra (Uchihara et al., 1992), nucleus coeruleus (Busch et al., 1997) and 
raphe nuclei (Aletrino et al., 1992) of AD patients. 
In addition to the microscopic pathology mentioned above, AD brain exhibits 
pronounced macroscopic atrophy leading to widening of the sulci, shrinkage of the gyri and 
enlargement of the ventricles (Fig. 3). This atrophy is represented by reduced weight in 
addition to volumetric reduction that can be detected by magnetic resonance imaging (MRI) 
and is primarily pronounced in the hippocampus, the entorhinal cortex and the amygdala 
(Bottino et al., 2002). The middle frontal gyri are affected but to a lesser extent than the 
temporal cortex, whereas the occipital and sensorimotor cortices are relatively spared in AD 
patients (Thompson et al., 2001). 
1.2.4 Synaptic loss 
AD patients were shown to have synaptic loss in different layers of the temporal and 
frontal cortex (Davies et al., 1987). It has been shown recently that patients with mild AD had 
55% synaptic loss in the CA1 while patients with MCI exhibited 18% synaptic loss in 
comparison to control cases (Scheff et al., 2007). The degree of synaptic loss has been 
suggested to correlate with the duration of the dementia (Blennow et al., 1996). Since synaptic 
loss was found to parallel the cognitive state of the patients (Scheff et al., 2007), there was a 
significant correlation between synaptic count and the performance in the mini mental state 
examination (MMSE) in AD patients (DeKosky and Scheff, 1990). Besides, it has been 
suggested to be the major correlate to the cognitive decline in comparison to NFT and neuron 
loss (Terry et al., 1991; Scheff et al., 2007). This evidence is supported by the common 
knowledge that the synapses are the major sites for long term potentiation (LTP) and plasticity 






Many neurodegenerative diseases, such as 
Parkinson’s disease, amyotrophic lateral sclerosis and AD, 
exhibit prominent axonal transport deficits which manifest 
as axonal swellings (De Vos et al., 2008). In early-AD 
patients, axonal abnormalities have been detected in many 
brain regions, such as the hippocampus (Probst et al., 
1983), the cerebral cortex and subcortical regions such as 
the substantia nigra (McNeill et al., 1984) and the 
nucleus basalis of Meynert (Stokin et al., 2005), 
suggesting that axonal transport impairment plays a role 
during the pathology of the disease. Moreover, in vivo MRI studies illustrated that axonal 
transport is also altered in rodent models of AD (Smith et al., 2007).  
Axonal swellings in AD have been shown to accumulate axonal cargoes or proteins 
like tau (Kowall and Kosik, 1987), phosphorylated tau, choline acetyltransferase, APP (Wirths 
et al., 2007), ubiquitin (Cras et al., 1991) and cellular organelles (Stokin et al., 2005). It is 
noteworthy to mention two types of axonal swellings present in the AD brain. The first type is 
dystrophic neurites seen in the vicinity of plaques that are formed in response to plaque 
deposition (Terry et al., 1964; Cras et al., 1991). Unlike plaque-dependent dystrophic neurites, 
plaque-independent axonal spheroids precede aberrant amyloid deposition or tau 
hyperphosphorylation and might rather represent a precursor for plaque deposition (Stokin et 
al., 2005) (Fig. 4). 
 
1.3 Diagnosis and treatment 
1.3.1 Diagnosis 
Definite diagnosis of AD can only be achieved by examining postmortem tissue for 
amyloid plaques and NFTs. Nevertheless, the medical history of the patient obtained from a 
third informant is a basic practice in the diagnosis. Neurological and physical examinations 
serve as important parts of the differential diagnosis of the dementia. Also, cognitive 
assessment is an essential requirement especially at the early stages because it can detect 
Fig 4. Axonopathy in AD. APP-
positive axonal spheroids (arrow 
heads) in the spinal cord of an AD 
patient (Wirths et al., 2007). 
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memory impairments (Waldemar et al., 2007). This involves neuropsychological tests 
covering different cognitive entities, such as MMSE (Folstein et al., 1975). Blood tests are 
necessary to identify secondary causes of dementia and coexisting disorders that are common 
in elderly people. Neuroimaging (MRI and CT), is mainly used to exclude alternative causes 
of dementia such as brain tumors and subdural haematoma (Waldemar et al., 2007). 
Measurements of atrophy in certain regions of the temporal lobe using MRI hold promise to 
differentiate AD from control cases (Killiany et al., 1993). Hypometabolism in the temporal, 
parietal, and posterior cingulate cortex, identified by 
18
F-fluorodeoxyglucose-positron 
emission tomography (PET), could be used to differentiate patients with AD from cognitively 
normal elderly people with high sensitivity and with a relatively good specificity to other 
dementias (Silverman et al., 2001; Herholz et al., 2002). In addition, cerebral spinal fluid 
(CSF) biomarkers, such as reduced Aβx-42 and increased tau and phosphorylated tau, have 
been investigated as valuable diagnostic biomarkers for AD (Mattsson et al., 2009).  
 
1.3.2 Treatment 
Despite all the vast efforts to investigate therapeutics for AD, there is presently no 
cure. The available AD treatments target the symptoms and do not address the underlying 
molecular mechanism of the disease. Four drug-treatments, which target neurotransmitter 
disturbances in AD, are currently approved. These include the drug memantine and three 
acetylcholinesterase inhibitors. In addition, some antipsychotic drugs are moderately effective 
in alleviating some AD symptoms, such as aggression and psychosis (Ballard and Waite, 
2006). 
Memantine is a non-competitive N-methyl D-aspartate (NMDA)-receptor antagonist. 
It works by protecting neurons from glutamate-mediated excitotoxicity that is increased in AD 
without preventing the physiological NMDA-receptor activation needed for cognitive 
functioning. Memantine shows modest effects in moderate to severe AD cases (Areosa et al., 
2005).  
 The cholinergic hypothesis postulates that the activity of cholinergic neurons is 
disturbed in AD, leading to cognitive and memory impairment (Terry and Buccafusco, 2003). 
With this notion in mind, three drugs, donepezil, rivastigmine and galantamine, are used to 
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increase the availability of acetylcholine by inhibiting acetylcholinesterase, the enzyme that 
degrades acetylcholine in the synaptic cleft. Rather than changing the natural course of AD, 
they only temporarily mitigate some of the symptoms (Bullock and Dengiz, 2005; Bullock et 
al., 2005; Winblad et al., 2006).  
 
1.4 The amyloid precursor protein 
The similarities in the brain pathology between AD and Down syndrome (DS) raised 
the question of whether a common molecular basis underlies the pathology in both situations. 
The localization of the defective gene in familial AD (FAD) to the DS region of chromosome 
21 provided an explanation for the AD phenotype seen in DS (St George-Hyslop et al., 1987). 
The defective gene was shortly isolated and described to be a single transmembrane 
glycoprotein, the amyloid precursor protein (APP) (Kang et al., 1987; Tanzi et al., 1987). 
APP belongs to a gene family that includes amyloid precursor like protein-1 (APLP-1) 
and APLP-2 which are type-1 transmembrane proteins and share significant sequence 
homology in their ectodomains; the Aβ sequence, however, is unique to APP (Bayer et al., 
1999). The APP gene encodes three major isoforms, APP695, APP751 and APP770, resulting 
from alternative splicing (Kang et al., 1987; Kitaguchi et al., 1988; Tanzi et al., 1988). 
APP770 and APP751 are expressed widely in non-neuronal cells throughout the body but also 
expressed in neurons. APP695, which is expressed predominantly in neurons (Sola et al., 
1993), is the most abundant form in the brain. In both human and rodents, APP expression 
shows wide distribution in the brain with the highest expression in the cortex, hippocampus 
and cerebellum. APP was reported in many other brain regions such as the basal ganglia 
(nucleus basalis of Meynert) and the substantia nigra (Sola et al., 1993). In neurons, APP is 
expressed in neuronal perikarya, transported by fast anterograde axonal transport and found in 
the nerve terminals, dendrites and synapses (Koo et al., 1990). 
Although the pathological role of APP has been extensively studied since its 
discovery, the physiological role is still undetermined. APP has been suggested to be involved 
in cell adhesion, neurite growth, synaptogensis, neuronal transport of proteins, transmembrane 
signal transduction and calcium metabolism (Zheng and Koo, 2011). However, studies have 
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shown that APP null mice are viable and fertile despite their reduced body weight, locomotor 
activity, cognitive impairment and reduced LTP in addition to gliosis (Dawson et al., 1999).  
After its synthesis in the endoplasmic reticulum (ER), APP is subject to 
posttranslational modifications such as glycosylation, sulfation, and phosphorylation during its 
transit through the intracellular protein secretory pathway (Selkoe, 2001). APP isoforms exist 
such as the immature form (imAPP) that is localized to the ER and cis-Golgi and not subject 
to cleavage by secretases. imAPP is then trafficked though the Golgi to yield the mature APP 
(mAPP) (Tomita et al., 1998). mAPP in neurons is phosphorylated after transit through the 
Golgi apparatus, just preceding APP targeting out of neuronal perikarya into the axons 
(Suzuki et al., 1997). Phosphorylation of APP is suggested to regulate its subcellular 
trafficking, production of Aβ, cell signaling and protect it against degradation by caspases 
(Lee et al., 2003; Suzuki and Nakaya, 2008). 
 
1.4.1 Non-amyloidogenic pathway 
There are two major alternative pathways for APP processing that differ in the 
enzymes involved as well as in the resulting peptides. In the non-amyloidogenic pathway, 
alpha secretase (α-secretase) cleaves APP twelve amino acids from the transmembrane 
domain at the N-terminal. This cleavage occurs in the Aβ domain and demolishes the 
production of Aβ (Sisodia et al., 1990). It occurs primarily at the plasma membrane resulting 
in shedding of the soluble ectodomain fragment (sAPPα) into the lumen/extracellular space 
and retention of an 83-residue C-terminal fragment (CTFα) in the membrane (Sisodia, 1992). 
α-Secretase is a single transmembrane type-1 protein which was found to be zinc-dependent 
(Roberts et al., 1994) (Fig. 5). Enzymes belonging to ADAM (a disintegrin and 
metalloproteinase) family such as ADAM 9, ADAM 10 and ADAM 17 have been suggested 
to have α-secretase activity (Buxbaum et al., 1998; Koike et al., 1999; Lammich et al., 1999). 
The remaining CTFα is further processed by gamma secretase (γ-secretase) to release the 





















1.4.3 Amyloidogenic pathway 
The amyloidogenic pathway involves the cleavage of APP by beta secretase (β-
secretase), which cuts 16 amino acids upstream from the α-secretase cleavage site to generate 
a soluble amino terminal APP derivative (sAPPβ), and a membrane inserted C-terminal 
fragment that is 99 amino acids long (CTFβ). After the initial β-secretase cut, γ-secretase 
cleaves the CTFβ at different intramembranous sites to yield Aβ peptides of varying lengths 
(39 – 43 amino acids) consisting mostly of Aβ that is 40 amino acids long (Aβx-40) and a 
smaller amount of Aβ that is 42 amino acids long (Aβx-42) in addition to the AICD (Citron et 
al., 1995; Haas et al., 1995; Selkoe, 2001; Tang, 2009). 
The beta site APP-cleaving enzyme (BACE) was identified as β-secretase 
concomitantly by several groups (Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999). 
BACE1 (or Asp2) is a membrane-bound aspartyl protease with a characteristic type-1 
transmembrane domain near the C-terminus that cleaves Aβ at known positions; the aspartate 
at position 1 or the glutamate at position 11 (Sinha et al., 1999; Vassar et al., 1999). BACE1 is 
Fig. 5. APP processing. Schematic representation showing the non-amyloidogenic processing 
via α-secretase and γ-secretase to produce p3 (right) and the amyloidogenic precessing via 
BACE1 (β-secretase) and γ-secretase to produce amyloid plaque-forming Aβ (left). Taken 
from (Tang et al., 2009) 
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highly expressed in the brain, especially in the hippocampus, the cortex and the cerebellum, 
and is considered the major β-secretase for the generation of Aβ peptides by neurons (Vassar 
et al., 1999; Cai et al., 2001). At a subcellular level, BACE1 is predominantly localized within 
endosomes, with lower levels in the trans-Golgi network (TGN) and the cell membrane; it is 
absent from lysosomes and the ER (Huse et al., 2002). Very little BACE1-mediated APP 
cleavage occurs at the plasma membrane because it is recycled very quickly, precluding 
substrate cleavage. Instead APP is cleaved by BACE1 primarily in endocytic vesicles (Chow 
et al., 2011). In addition to BACE1, BACE2 and cathepsin B have been suggested to exert β-
cleavage of APP, but their physiological contribution to APP cleavage is still debatable 
(Zhang et al., 2011).  
γ-Secretase consists of at least of four components: presenilin (PS; PS1 or PS2), 
nicastrin, anterior pharynx-defective-1 (APH-1) and presenilin enhancer-2 (PEN-2) (Kimberly 
et al., 2003) (Fig. 6). This complex is suggested to reside primarily in the ER, Golgi/TGN, 
endocytic and intermediate compartments (Cupers et al., 2001). Besides cleaving APP CTFs, 
γ-secretase cleaves other substrates such as notch, cadherin, tyrosinase, ErbB4 and CD44 
(Wolfe, 2010). Cleavage of APP CTFs was suggested to occur in TGN and in the early 











1.4.3 Aβ aggregation 
In vitro and in vivo analysis of amyloid deposits in AD revealed various N- and C-
terminal variants (Masters et al., 1985b; Suzuki et al., 1994a). Although the predominant Aβ 
Fig 6. Topology of γ-secretase complex. γ-Secretase consists of four components which are 
presenilin, nicastrin, PEN-2 and APH-1. The black bar represents the cleavage site for processing 
of PS1 into the amino and carboxyterminal fragments that self associate and form the active 
enzyme. Taken from (Gandy, 2005). 
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species in congophilic amyloid angiopathy (CAA) was suggested to be Aβx-40 (Glenner and 
Wong, 1984), the major C-terminal Aβ isoform in plaques was found to be Aβx-42 (Prelli et al., 
1988; Miller et al., 1993). The increased C-terminal length of Aβ in AD appears to cause the 
enhanced aggregation, early deposition and promote the toxicity of Aβ (Barrow and Zagorski, 
1991; Iwatsubo et al., 1994; Pike et al., 1995).  
The properties of Aβ peptides enable it to self-associate into different aggregation 
states ranging from monomers, soluble oligomers and insoluble fibrils. Aβ can produce 
oligomers ranging from dimers to high molecular weight structures (larger than 100 kDa), 
although, the majority of Aβ occurs in lower molecular weight ranges, from dimers to 
octamers. Soluble Aβ oligomers are low molecular weight, non-fibrillar, soluble structures 
which remain stable in aqueous solution even after high speed centrifugation (Walsh and 
Selkoe, 2007). Aβ monomers are suggested to be in equilibrium with different oligomeric 
isoforms. When a certain threshold of monomers is reached, polymerization into paranuclei is 
favored. These paranuclei self associate to form protofibrils which are beaded chains of 5 nm 
in diameter and less than 150 nm in length. Maturation of these protofibrils yields either the 
classical fibrils (around 10 nm in diameter and often more than 1 μm in length) comprising 
amyloid plaques, or alternatively, they can depolymerize to lower-order species (Walsh and 











Fig 7. Aβ aggregation. Aβ is a natively disordered protein, existing in the monomeric state as an 
equilibrium mixture of many conformers. Formation of a partially folded monomer is required to 
produce a nucleus for fibril elongation, a paranucleus (in this case, containing six monomers). 
Paranuclei self associate readily (to form protofibrils which comprise a significant but finite 
number of paranuclei. Maturation of protofibrils yields the classical amyloid-fibrils. Adapted from 
(Roychaudhuri et al., 2009). 
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1.5 The amyloid hypothesis  
For more than two decades, the amyloid hypothesis has been the cardinal hypothesis 
describing AD etiology. The amyloid hypothesis considers Aβ deposition to be the causative 
event of AD pathology; neurofibrillary tangles, cell loss, vascular damage and dementia occur 
as a consequence of this event (Hardy and Allsop, 1991). The evolution of this hypothesis was 
supported by many observations. One of the strongest arguments for the amyloid hypothesis 
came from genetic studies which brought to light many FAD cases that resulted from inherited 
APP or PS1 mutations leading to increased deposition of Aβ in plaques (Bertram et al., 2010). 
In addition, triplication of the APP gene in DS patients leads to AD pathology in these patients 
(St George-Hyslop et al., 1987). Moreover, transgenic models of AD harboring APP 
mutations develop age-dependent pathology similar to that seen in AD (Philipson et al., 2010). 
Also, the fourth allelic variant (ε4) of the apolipoprotein (APOE) polymorphism, which 
represents the most important genetic risk factor for the sporadic form of AD, is associated 
with Aβ accumulation and reduced clearance (Castellano et al., 2011). On the other hand, 
mutations in tau lead to taupathies and not AD, thereby suggesting that NFTs occur 
subsequent to Aβ aggregation. 
One of the major flaws in the amyloid hypothesis is the weak correlation between the 
severity of the dementia and the density of amyloid plaques (Snowdon, 2003). Reciprocally, 
cognitive impairments and pathological changes in many AD mouse models occur before the 
first signs of the plaque deposition (Klein et al., 2001; Walsh and Selkoe, 2007). Johansson et 
al. (2007) studied the effect of the polyunsaturated fatty acid docosahexaenoic acid on Aβx-42 
oligomerization and fibrillization in vitro and showed that it stabilized soluble Aβx-42 
protofibrils, thereby hindering their conversion to insoluble fibrils and hence maintaining Aβ-
induced toxicity over time. On the other hand, Aβx-42 devoid from docosahexaenoic acid 







Fig 8. Representation of the intraneuronal Aβ hypothesis. (Wirths et al., 
2004). 
1.5.1 The intraneuronal amyloid hypothesis  
The neuronal 
origin of the extracellular 
plaques is one of the 
accepted facts in the field 
of AD. In vitro studies 
have elucidated the 
presence of intraneuronal 
Aβ in cultured human 
neurons (Wertkin et al., 
1993; Turner et al., 
1996). The first 
observations about the 
presence of Aβ in 
neurons, and that it 
precedes plaque 
deposition in AD cases, 
date back more than 20 
years (Masters et al., 1985a; Grundke-Iqbal et al., 1989). Moreover, a study by Gouras et al. 
showed that intraneuronal Aβx-42 accumulates in AD vulnerable regions and that this 
deposition precedes NFTs and extracellular plaques (Gouras et al., 2000). A similar finding 
was made in young DS patients lacking plaque deposition. This observation led to the 
suggestion that intracellular Aβ deposition precedes extracellular deposition and pathological 
consequences (Gyure et al., 2001). An increasing amount of data regarding intraneuronal Aβ 
in AD has accumulated in the past years showing the correlation between intraneuronal Aβ, 
neuron loss and cognitive impairments in several mouse models of AD (Wirths and Bayer, 
2010) (Fig. 8).  
Converging evidence points toward two different origins of intraneuronal Aβ: 
intracellular processing of APP and reuptake of Aβ from the extracellular space. Extensive 
studies support the role of intracellular APP processing in the accumulation of intraneuronal 
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Aβ. Several reports have shown that Aβx-42 is generated in the ER/intermediate compartments 
and TGN while Aβx-40 is generated exclusively in the TGN (Cook et al., 1997; Hartmann et 
al., 1997; Greenfield et al., 1999). It has been suggested that clathrin mediated endocytosis of 
cell surface APP leads to the production of Aβ via the endocytic pathway (Koo and Squazzo, 
1994).  
In addition to intracellular production of Aβ, extracellular reuptake of Aβ represents 
another source of intraneuronal Aβ. Several pathways have been proposed for the 
internalization of Aβ like APOE receptors, endocytosis, nicotinic acetyl choline receptors, 
integrins, NMDA receptors and the receptor for advanced glycation end products (Mohamed 
and Posse de Chaves, 2011). 
Accumulation of Aβ in lysosomes leads to the loss of lysosomal impermeability and 
leakage of lysosomes’ content, such as cathepsins and proteases, resulting in necrosis and 
apoptosis (Ditaranto et al., 2001; D'Andrea et al., 2002). Also, accumulation of Aβ in 
multivesicular bodies (MVBs) might hinder their function in retrograde transport and 
degradation. This is particularly important since MVBs represent a good medium for Aβ 
aggregation due to their abundant membranes and acidic environment (Takahashi et al., 2002). 
In vitro and in vivo studies have shown that accumulation of intraneuronal Aβ impairs 
protease activity and leads to tau accumulation (Tseng et al., 2008). Moreover, the localization 
of Aβ to mitochondria in APP models correlated with a reduced rate of oxygen consumption, 
increased hydrogen peroxide and decreased respiratory chain enzymes activity (Caspersen et 
al., 2005; Manczak et al., 2006). Studies from AD mouse models and AD patients showed a 
correlation between intraneuronal Aβ and apoptotic markers (Chui et al., 2001). 
All together, these findings from AD patients, DS patients, mouse models and in vitro 
studies led to a twist in the amyloid hypothesis which identifies intraneuronal Aβ as a key 




AD is a multifactorial disease that is influenced by many environmental and inherited 
factors, with aging as the major risk factor for the disease. After the age of 65, the risk of 
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developing AD doubles every 5 years; thus, the global incidence of AD raises as the average 
age of the worldwide population increases (Ferri et al., 2005). Besides aging, low educational 
and occupational attainment, low mental ability in early life and reduced mental and physical 
activity during late life have been suggested to increase the risk of AD (Whalley et al., 2000; 
Scarmeas et al., 2001; Lindsay et al., 2002). Other factors may include traumatic head injuries, 
depressive mood and excessive alcohol consumption (Mayeux, 2003). Moreover, a 
particularly high risk of developing AD has been shown for smokers and patients with 
hypertension, diabetes or hyperlipidemia (Lange-Asschenfeldt and Kojda, 2008).  
The vast majority of AD cases are sporadic, while 5 to 10% are familial AD cases 
(FAD) caused by inherited mutations usually leading to early onset AD. Early onset AD 
includes patients who range from 16 to 65 years of age; whereas late onset AD includes 
patients older than 60 years. Genetic studies of FAD revealed three main gene mutations in 
the APP, PS1 and PS2 genes. These mutations account for only 30-50% of the cases with 
autosomal dominant AD (Bekris et al., 2010). 
The first mutation detected in the APP was discovered in British kindred and thus 
called the London mutation (Goate et al., 1991). Currently, more than 32 APP missense 
mutations have been identified in 89 families (Department of molecular genetic, University of 
Antwerp, 2011). All APP mutations identified so far lie in or near the Aβ sequence. The 
majority of APP mutations are in the vicinity of protease cleavage sites, exerting their 
pathogenic effect by influencing APP cleavage and altering the Aβx-42/Aβx-40 ratio. However, 
the Swedish mutation at the β-secretase cleavage site increases the overall Aβ levels (Mullan, 
1991; Citron et al., 1992). Mutations near the γ-secretase cleavage site affect the C-terminal 
cleavage position. The London mutation (APP717) near the γ-secretase cleavage sites leads to 
an increase in the Aβx-42 over Aβx-40 ratio without affecting the overall Aβ production (Suzuki 
et al., 1994b). The same holds true for the Florida mutation (APP716) mutation (Eckman et 
al., 1997). Mutations at the α-secretase cleavage site, such as the Flemish mutation (APP692), 
interfere with α-secretase cleavage, giving more substrate for the β-secretase (Cras et al., 
1998). On the other hand, mutations within the Aβ sequence may alter the physiochemical 
properties of Aβ, leading to enhanced aggregation and increased protofibril/fibril formation, 
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Fig 9. Some of the AD missense mutations. The Swedish mutation increases β-secretase cleavage, while the 
Flemish mutation partly disfavors α-cleavage of APP. The Arctic, Dutch and Iowa mutations mainly increase 
aggregation. The London-type APP mutations increase Aβx-42 or the Aβx-42 ⁄Aβx-40 ratio by altering the γ-
secretase cleavage site. Taken from (Gandy, 2005). 
an observation seen in the Dutch and the Arctic mutations (Nilsberth et al., 2001; Brouwers et 
al., 2008) (Fig. 9). 
 
Linkage studies revealed the presence of another locus on chromosome 14 related to 
FAD which corresponds to the PS1 gene. Mutations in PS1 are the most common causes of 
FAD, accounting for 18-50% of cases of FAD. To date, 182 PS1 mutations have been 
identified in 402 families (Department of molecular genetic, University of Antwerp, 2011). 
Besides being the most common FAD mutation, it accounts for the most aggressive and early 
form of the disease, characterized by an onset of 30 years of age (Bekris et al., 2010). In 
addition to mutations in PS1, mutations in PS2 gene on chromosome 1 were identified; 
however, they represent a rare cause of FAD. So far, 13 mutations in the PS2 have been 
described in 22 families (Department of molecular genetic, University of Antwerp, 2011). PS1 
and PS2 mutations are known to cause an increase in Aβx-42/Aβx-40 ratios either by increasing 
Aβx-42 or by decreasing Aβx-40 levels (Kumar-Singh et al., 2006).  
Although genetic mutations account for a minority of AD cases, several genetic 
polymorphisms have been suggested to be associated with sporadic AD such as the fourth 
allelic variant (ε4) of APOE, which represents the strongest genetic risk factor. The presence 
of the APOE ε4 allele increases the risk of the disease by 3-fold in heterozygous carriers and 
by 15-fold in homozygous carriers (Farrer et al., 1997). Other susceptibility loci that might 
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contribute, but to a lesser extent, to the risk of developing AD include clusterin (CLU), 
complement component (3b/4b) receptor 1 (CR1) and phosphatidylinositol-binding clathrin 
assembly protein (PICALM) (Sleegers et al., 2010). 
 
1.7 Mouse models of Alzheimer’s disease 
Transgenic mouse models of AD have been developed based on the amyloid 
hypothesis and advanced from the contentious discovery of mutations in FAD. AD mouse 
models, like other disease models, contribute widely to the understanding of the 
pathophysiology of the disease. Furthermore, they have been invaluable tools in the 
preclinical testing of potential therapeutics such as immunotherapies. Whereas invertebrate 
models such as Drosophila melanogaster and Caenorhabditis elegans are available for 
various diseases, including AD, and might offer certain advantage over mouse models, they 
are evolutionarily distant from humans. Mice, on the other hand, are the most commonly used 
vertebrates for transgenic modeling due to their relatively short life span, low costs and easy 
handling. Moreover, the use of mice has been facilitated by the availability of advanced 
techniques and knowledge of genetic modification. Although some transgenic rats have been 
described recently (Philipson et al., 2010), mice are almost the exclusive transgenic mammals 
used to model AD. 
The discovery of the FAD mutations in APP provided the opportunity to study AD 
through the generation of AD models carrying these mutations. This was started with the 
generation of a mouse model that overexpresses the Indiana mutation, V717F, under the 
platelet-derived growth factor. This drives the expression of the transgene in the CNS and the 
periphery, leading to an 18-fold increase in APP levels. As a consequence, the mice exhibit an 
age-dependent increase in plaque deposition starting from 6 months of age, in addition to 
dystrophic neurites, astrocytosis, microgliosis and synaptic loss (Games et al., 1995; 
Rockenstein et al., 1995). These mice show deficits in object recognition memory which were 
found to be related to the number of amyloid deposits in specific brain regions, whereas 
deficits in spatial reference and working memory were related to the changes in synaptic 
density and hippocampal atrophy (Dodart et al., 2000). The Tg2576 mouse is one of the most 
widely studied models, expressing the Swedish mutation under the control of the hamster 
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prion protein promoter. It develops plaque pathology around 9-12 months of age together with 
astrocytosis, microgliosis, dystrophic neurites and impairments in different forms of memory 
such as spatial and working memory (Hsiao et al., 1996). Moreover, other mouse models with 
multiple APP mutations have been generated to drive early AD pathology such as the 
TgCRND8 mouse model (Chishti et al., 2001). 
Many PS models have been generated, either using similar promoters to the APP 
models, such as the PS1 M146L model (Duff et al., 1996), or as targeted genes, such as the 
PS1M146VKI model (Guo et al., 1999). In general, PS1 models exhibit increased Aβx-42 
levels, but they do not develop an overt deposition of plaques or other AD hallmarks, unless 
they are crossed to APP transgenic mice (Holcomb et al., 1998). The lack of plaque deposition 
in the PS1 models might be due to the low Aβx-42 levels in comparison to APP models. It 
might also be caused by differences in the solubility and aggregation properties between 
mouse and human Aβ (Jankowsky et al., 2007). 
Although AD mouse models represent a wide spectrum of AD pathology, they are 
hampered by the lack of some cardinal features of AD, such as neuron loss and NFTs. Among 
APP models, only APP23, with the Swedish mutation under the Thy-1 promoter, harbors 
neuron loss in the CA1 region at 14-18 months of age (Calhoun et al., 1998). More 
widespread neuron loss has been reported in mouse models which coexpress APP and PS1 
mutations, such as the APP/PS1KI (Casas et al., 2004), APP/PS1 (Schmitz et al., 2004) and 
5XFAD mouse models (Oakley et al., 2006). Hence, neuron loss seems to be detected in mice 
where a combination of multiple mutations is expressed. 
Another weakness is the lack of NFTs in AD models. In order to overcome this, FAD 
and tau mutations from frontotemporal dementias were combined in mice like the tau/APP 
mice resulting from the crossing of Tg2576 and P301 mice (Lewis et al., 2001). A triple 
transgenic model, 3xTg, was generated by coinjecting two transgenes containing APP-
Swedish and P301L mutations into PS1M146V knock-in mice (Oddo et al., 2003). Both 




1.8 The 5XFAD mouse model 
The 5XFAD model is a double 
transgenic APP/PS1 mouse model that 
co-expresses five AD mutations 
leading to accelerated plaque 
formation and increased Aβx-42 
production. The model was generated 
by introducing APP Swedish, Florida 
and London mutations, and PS1 
M146L and L286V mutations into 
APP (695) and PS1 cDNAs via site-
directed mutagenesis. They were later sub-cloned into mouse Thy-1 transgenic cassette. The 
originally described 5XFAD mice were maintained in a hemizygous state on a C57/BL6SJL 
background. The mice showed stable transmission and expression of both APP and PS1 
transgenes over generations, demonstrating that the 5XFAD mice breed as a single transgenic 
model (Oakley et al., 2006). 
The presence of Swedish mutation results in higher levels of the total Aβ, whereas 
Florida, London, M146L and L286V mutations increase the production of Aβx-42 specifically 
(Fig. 10). Therefore, 5XFAD mice show a dramatic increase in Aβx-42 in comparison to Aβx-40 
which is proportional to the APP expression. This is reflected by an early onset of plaque 
deposition (around 2 months of age) that spreads to cover most of the brain paralleled with 
astrocytosis and microgliosis (Oakley et al., 2006). Interestingly, 5XFAD mice exhibit a 
gender-based effect. This was illustrated when mice showed a gender-specific response to 
stress in which female mice exhibited a significant increase in hippocampal plaque deposition 
that was not seen in male mice (Devi et al., 2010). 
In addition to plaque pathology and gliosis, the 5XFAD model was reported to develop 
age-dependent synaptic degeneration indicated by the reduction of synaptic markers (Oakley 
et al., 2006). Intraneuronal BACE1 and Aβ colocalize to swollen presynaptic terminals and 
fine axonal processes before plaque deposition. Later, these structures undergo a continuing 
Fig 10. Schematic diagram of the 5XFAD, APP and PS1, 
transgenes. FAD mutations in Thy1–APP and Thy1–PS1 
transgenes are indicated by arrowheads. Sw, Swedish 
mutation; Lon, London mutation; Fl, Florida mutation. Small 
gray rectangles represent coding regions of APP and PS1. 
Taken from (Oakley et al., 2006). 
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process of sprouting/swelling and dystrophy, associated with the emergence and deposition of 
extracellular Aβ (Zhang et al., 2009).  
  The 5XFAD mouse model represents an important model as it is one of the few 
currently available AD mouse models known to develop neuron loss. 5XFAD mice were 
reported to develop neuron loss by 9 months of age at the cortex and subiculum (Oakley et al., 
2006). Genetic deletion of BACE in the 5XFAD/BACE knockout mice rescues the neuron 
loss in these mice in comparison to 5XFAD mice (Ohno et al., 2007). However, neuron loss in 
the 5XFAD mice was never appropriately quantified. 
As a consequence of the extensive pathology seen in the 5XFAD mouse model, this 
model develops different behavioral impairments. 5XFAD mice were found to develop 
working memory impairments in the Y-maze as they reached an age of 4 to 5 months (Oakley 
et al., 2006). In addition, 5XFAD mice exhibit impairment in the contextual fear conditioning 
as early as 4 months of age, which correlates with hippocampal synaptic dysfunction (Kimura 
and Ohno, 2009). At 9 months of age, these mice are impaired in the conditioned taste 
aversion test, which can be rescued to the wild type performance by partially abolishing 
BACE (heterozygous knock-out) (Devi and Ohno, 2010). 
All together, the variety of AD hallmarks presented by the 5XFAD model prompted its 
use recently to assess different potential therapeutic interventions, such immunization (Wirths 
et al., 2010b), somionine (Joyashiki et al., 2011), PKC activator (Hongpaisan et al., 2011), 
agonists of the peroxisome proliferator activated receptor gamma (PPARgamma) (Kalinin et 
al., 2009) and icariin (Urano and Tohda, 2010).However, as this model lacks NFTs formation, 
it represents an amyloid-predominant model of AD. 
 
1.9 The pyroglutamate-modified Aβ  
In order to unravel the pathogenic properties of Aβ, it was important to develop 
approaches to extract and study the biochemical nature of Aβ. Limited extraction and 
sequencing methods rendered it impossible for a long time. Masters et al. reported the 
presence of ragged N-termini of Aβ extracted from the plaque cores of AD and DS patients 
(Masters et al., 1985b). According to them, 64% of the total Aβ peptides started with 
phenylalanine at position 4. Soon after that, Selkoe and colleagues reported that they were not 
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able to obtain N-terminal sequences from plaques. Thus, they postulated that the N-terminal of 
Aβ might be blocked (Selkoe et al., 1986). In line with these suggestions, other teams did not 
succeed in obtaining interpretable N-terminal sequences from plaque cores isolated by other 
methods (Gorevic et al., 1986). Finally, this discrepancy was resolved by Mori and colleagues 
who described the presence of Aβ peptides (15-20% of the total Aβ) bearing a pyroglutamate 
residue at the N-terminus. By using pyroglutamate amino peptidase, they were able to unravel 
the N-terminus, which is blocked by the lactam ring and thus resistant to any other peptidase 
previously used for Edman sequencing (Mori et al., 1992).  
Since then, the interest in dissecting the temporal and spatial deposition of 
pyroglutamate-modified Aβ (AβpE3-x) has increased. Many techniques and protocols were 
developed in order to increase the sensitivity to different forms of Aβ, especially the AβpE3-x 
peptides (Naslund et al., 1996; Thompson et al., 1999). Equipped with a set of novel 
antibodies, Saido et al. showed by immunohistochemical and biochemical means that AβpE3-x 
is present in equivalent or larger amounts than full-length Aβ in senile plaques. Based on the 
analysis of brain tissue from DS cases, the authors also suggested that AβpE3-x precedes the 
deposition of unmodified Aβ (Aβ1-x) (Saido et al., 1995). However, a study on the sequential 
deposition of heterogenous forms of Aβ in the brains of DS patients could not detect AβpE-x in 
young patients. Nevertheless, in agreement with Saido et al., AβpE-x always exceeded the 
deposition of Aβ1-x (Lemere et al., 1996). This was further confirmed by another study on 
water-soluble Aβ demonstrating the presence of AβpE3-42 in AD and DS as a dominant fraction 
(Russo et al., 1997). In line with the previous findings, testing extracts from AD and DS 
frontal cortex using ELISA revealed that levels of AβpE3 and isomerized Aβ species ending at 
amino acid 42 were higher than those ending with amino acid 40 (Hosoda et al., 1998; 
Harigaya et al., 2000). This was further confirmed by the observation that AβpE3-42 constituted 
25% of the total Aβ x-42 in plaques of AD brains (Harigaya et al., 2000). It was reported that 
unmodified Aβ1-40 and Aβ1-42 can be modified into AβpE3-42 after being injected into rat brain, 
indicating that rat brains harbor the enzymes required for N-terminal truncation and 
pyroglutamate formation (Shin et al., 1997). Interestingly, aged dogs, monkeys and bears, 
which share the same Aβ sequence, harbored AβpE3-x in plaques and CAA (Tekirian et al., 
1998; Chambers et al., 2010; Hartig et al., 2010). 
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1.9.1 Generation of pyroglutamate-modified Aβ  
Formation of AβpE-x is a multistep process requiring the removal of the first two amino 
acids aspartate and alanine in order to expose the N-terminal glutamate at the third position of 
Aβ. After cleavage of APP by β- and γ-secretase, Aβ1-40/42 is liberated. Data from our group 
suggest that the levels of AβpE3-x are inversely linked to the levels of Aβ1-x in plaques in 
APP/PS1KI transgenic mice (Wirths et al., 2010a). In line with this observation, Sevalle et al. 
suggested that aminopeptidase A can cleave the first amino (aspartate) from Aβ (Sevalle et al., 
2009). Interestingly, more than 15 years ago, Saido et al. suggested the presence of 
hypothetical peptidases cleaving the first two amino acids (Saido et al., 1995). On the other 
side, Aβ(E)11-x starting with a glutamate residue is known to be generated by alternative 
BACE1 cleavage of APP in the TGN (Huse et al., 2002), and is the precursor for AβpE11-x. 
After exposure of the glutamate, the enzyme glutaminyl cyclase (QC) catalyses pyroglutamate 
formation by dehydration of glutamate (Schilling et al., 2004).  
 
1.9.2 Biochemical properties of pyroglutamate-modified Aβ  
The conversion of Aβ into AβpE3-x leads to altered biophysical and biochemical 
characteristics, pointing to changes in aggregation and stability. Saido et al. suggested that 
AβpE3-x and other modified Aβ species accumulate because of their limited degradation. The 
formation of the lactam ring and the loss of two negative charges and one positive charge 
result in higher hydrophobicity. In addition, the N-terminal pyroglutamate is resistant to 
degradation by peptidases. As a result, these factors give AβpE3-x peptides more stability and 
aggregation propensity (Saido et al., 1996). He and Barrow reported that AβpE3-x peptides 
show enhanced β-sheet formation and aggregation propensity in aqueous and hydrophobic 
media compared to full-length Aβ. They suggested that the loss of three charged groups 
facilitates and stabilizes β-sheet formation by reducing the level of unfavorable charge 
repulsion between strands (He and Barrow, 1999). Using a mixture of Aβ species, including 
AβpE3-x levels mimicking the amount present in AD patients, abundant globular structures and 
higher aggregation rates were observed. In contrast, the aggregation propensity using the 
mixture present in non-demented individuals was significantly lower (Piccini et al., 2005). 
29
Interestingly, AβpE3-x displayed up to a 250-fold accelerated formation of aggregates compared 
to Aβ1-x, irrespective of the C-terminus of Aβ (Schilling et al., 2006).  
Russo et al. claimed that AβpE3-40 is more toxic for neurons and astrocytes compared to 
full-length Aβ1-40 (Russo et al., 2001). Similarly, another study showed that an Aβ mixture 
similar to the ones found in the brain of AD patients increased cell membrane permeability, 
leading to reduced cell survival in neuroblastoma cells (Piccini et al., 2005).  
It is worth mentioning that in contrast to what has been described above, some studies 
have indicated that the secondary structure and toxicity of AβpE3-40/42 peptides are similar to 
that of Aβ1-40/42 peptides (Tekirian et al., 1999; Wirths et al., 2010b). In agreement, Youssef et 
al. showed that Aβ1-42 and AβpE3-42 exhibited similar effects on neuronal cytotoxicity in 
primary cortical neurons and on memory impairment after intracerebroventricular injection in 
wildtype mice (Youssef et al., 2008). 
 
1.10 Glutaminyl cyclase  
Glutaminyl cyclase (QC) is a metal-dependent acyl transferase that converts glutamine 
(or alternatively glutamate) into pyroglutamate via the liberation of ammonia (or water) 
(Schilling et al., 2003). The first isolation of QC was achieved from the latex of the tropical 
plant Carcia papaya (Messer, 1963). Twenty-four years later, a similar enzyme was detected 
in mammalian tissues such as brain, pituitary, adrenal medulla and human B lymphocytes 
(Busby et al., 1987; Fischer and Spiess, 1987). Later, RNA sequences homologous to that in 
Carcia papaya were identified in Arabidopisis thaliana, Solanum tuberosum and bacteria 
(Wintjens et al., 2006; Schilling et al., 2007). Although plant and animal QC seem to be 
similar in terms of their substrate and subcellular localization, cloning of several animal and 
plant QC showed differences in the primary structures (Pohl et al., 1991; Song et al., 1994; 
Dahl et al., 2000). This led to the assumption that the two enzymes evolved from different 
origins (Schilling et al., 2008a). However, both enzymes act by a similar mechanism. The 
active site of the human QC contains a zinc ion that facilitates the formation of a lactam ring 
after the removal of water molecule from glutamate (or the ammonia from glutamine) 
(Schilling et al., 2008a). 
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1.10.1 Physiological functions of glutaminyl cyclase 
QC has a wide range of substrates, which were described and investigated before the 
isolation of QC itself. QC is involved in the posttranslational maturation of many hormones, 
such as gonadotropin releasing hormone (GnRH) and thyrotrophin releasing homromone 
(TRH), as well as neuropeptide like neurotensin and orexin. In addition, other substrates for 
QC include protein matrixes, such as fibronectin, collagens, and chemokines, such as 
monocyte chemoattractant proteins 1 to 4. The presence of pyroglutamate protects proteins 
such as MCP, GnRH and TRH from degradation by amino peptidases (Sealfon et al., 1997; 
Van Coillie et al., 1998; Morty et al., 2006). Also, pyroglutamate has been shown to be 
essential for protein activity. The loss of pyroglutamate leads to reduced protein-receptor 
interaction, as shown for TRH and MCP (Goren et al., 1977; Van Coillie et al., 1998). 
 
1.10.2 The role of glutaminyl cyclase in the generation of pyroglutamate-modified Aβ  
It has been suggested that cyclization of glutamate to pyroglutamate can occur 
spontaneously, an assumption that was greatly influenced by the lack of methodological 
techniques. However, it was shown later that spontaneous cyclization is seventy times slower 
than enzymatic driven cyclization (Busby et al., 1987; Fischer and Spiess, 1987).  
Compelling evidence demonstrates the role of QC in the generation of AβpE-x. 
Incubation of synthetic Aβ3-x with recombinant QC resulted in the conversion into AβpE3-x. 
This reaction is favored under acidic pH conditions and blocked by the presence of a QC 
inhibitor (Schilling et al., 2004). Furthermore, QC stimulated AβpE3-x generation in two 
different cell lines (Cynis et al., 2006; Cynis et al., 2008a). Application of a QC inhibitor 
suppressed the cyclization reaction to AβpE3-x. Interestingly, addition of recombinant QC into 
culture media generated only minor amounts of AβpE3-x. This finding indicates that 
pyroglutamate Aβ formation is favored within intracellular compartments (Cynis et al., 
2008a).  
In agreement with in vitro studies, several in vivo reports have supported the role of 
QC in the production of AβpE3-x. Injection of Aβ3-40 into the cortex of wildtype rats led to 
significant production of AβpE3-40 within 24 hours, which was inhibited by co-application of a 
QC inhibitor (Schilling et al., 2008b). Oral administration of a QC inhibitor to Tg2576 and 
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TASD-41 transgenic mice reduced AβpE3-x, Aβx-40 and Aβx-42 levels. This was accompanied by 
a reduction in plaque load and gliosis in addition to improvements in contextual fear memory 
and spatial memory. Similarly, treatment of transgenic Drosophila expressing Aβ transgene, 



















Fig. 11. Generation of pyroglutamate-modified A. The first two N-terminal amino acids, aspartate and 
alanine, are cleaved off by an unknown mechanism, thereby exposing glutamate at position three of the N-
terminus of A. Subsequently, glutamate is post-translationally modified into N-terminal pyroglutamate 
(pE) by dehydration catalysed by glutaminyl cyclase (QC) activity. The novel peptide has altered 
biochemical properties with severe pathological consequences. The enhanced toxicity is likely due to the 
higher aggregation propensity and the longer bioavailability of the AβpE3-x oligomers. 
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2. Project I: “Characterization of the 5XFAD mouse model” 
2.1 Overview  
As mentioned earlier, the 5XFAD mouse model is an AD model overexpressing 
multiple APP and PS1 mutations which lead to accumulations of Aβx-42 far exceeding those of 
Aβx-40. The significance of this model comes from the early accelerated cerebral amyloid 
deposition associated with many AD pathological and behavioral hallmarks. It is one of the 
rare AD models suggested to exhibit neuron loss (Oakley et al., 2006). The major benefit of 
the 5XFAD mouse model comes from the segregation of the transgenes (APP and PS1) 
together, a plus for the breeding with other transgenic mice. 
The original 5XFAD mice were generated and described on a C57/BLSJL genetic 
background. 5XFAD mice used in the current study were backcrossed to C57BL/6J genetic 
background. This was important to facilitate the comparison to other mouse models used in 
our lab which are maintained on C57BL/6J genetic background. Therefore, it was a 
prerequisite to characterize the 5XFAD model in detail on the new genetic background 
especially that previous studies have shown that the genetic background may influence AD 
pathology (Carlson et al., 1997; Lehman et al., 2003; Lassalle et al., 2008; Glazner et al., 
2010). Moreover, it was important to verify the 5XFAD mouse model as an appropriate model 
to study AβpE3-x in order to use it to study the effect of QC on AD pathology.  
In the following manuscript, we performed longitudinal characterization of female 
5XFAD mice starting from 3 to 12 months of age. The behavioral performance of the 5XFAD 
mice was evaluated using a battery of motor and cognitive tasks. In order to evaluate neuron 
loss, an important hallmark of AD, stereological neuron counting was performed in 12-month-
old mice in different brain regions. In addition, age-dependent axonopathy and spinal cord 
pathology were quantified in different brain regions. Plaque load and intracellular Aβ were 
also assessed in an age-dependant manner for both the pool of pan Aβ and AβpE3-x.  
 
Aims of Project I 
- To validate the 5XFAD mouse model on the C57BL/6J genetic background.  
- To assess unexplored behavioral entities in the 5XFAD mouse model such as anxiety, 
motor function and explorative activity in an age-dependent manner. 
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- To quantify plaque pathology and axonopathy in different brain regions and in the 
spinal cord.  
- To quantify the previously assumed neuron loss using unbiased stereology and study 
how it relates to the presence of intraneuronal Aβ.   
- To replicate the memory impairment described in these mice. 


























2.2 Original publication  
 
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T.A., and Wirths, O. (2010). Motor deficits, 
neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta 
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bstract
In the present report, we extend previous findings in the 5XFAD mouse model and demonstrate that these mice develop an age-dependent
otor phenotype in addition to working memory deficits and reduced anxiety levels as demonstrated in an elevated plus maze task.
mploying a variety of N- and C-terminal specific A antibodies, abundant intraneuronal and plaque-associated pathology, including
ccumulation of pyroglutamate A, was observed as early as the age of 3 months. Using unbiased stereology, we demonstrate that the
XFAD mice develop a significant selective neuron loss in layer 5 of the cortex, leaving the overall neuron number of the total frontal cortex
nd hippocampus unaffected. This observation coincides with the accumulation of intraneuronal A peptides only in cortical Layer 5, but
ot in CA1, despite comparable APP expression levels. The motor phenotype correlates with abundant spinal cord pathology, as
emonstrated by abundant intraneuronal A accumulation and extracellular plaque deposition. In addition, comparable to the APP/PS1KI
ouse model, 5XFAD mice develop an age-dependent axonopathy likely contributing to the behavioral deficits.
2010 IBRO All rights reserved.


















Alzheimer’s disease (AD) is a severe neurodegenerative
isorder representing the most frequent form of dementia. It
s characterized by the deposition of extracellular plaques
omposed of the mainly 40–42 amino acid A peptide, as
ell as intracellular neurofibrillary tangles consisting of
yperphosphorylated Tau protein. Over the past years nu-
erous transgenic mouse models of AD have been gener-
ted, reflecting underlying pathological alterations (Duyck-
erts et al., 2008). Extracellular A deposition, as well as
herapeutic strategies for plaque removal, have dominated
esearch efforts in AD during the last years, however, the
resence of intraneuronal A accumulations has recently
* Corresponding author. Tel: 49 551 39 10290; fax: 49 551 39
0291.2E-mail address: owirths@uni-goettingen.de.
197-4580/$ – see front matter © 2010 IBRO All rights reserved.
oi:10.1016/j.neurobiolaging.2010.05.027
36ained in importance. It has been shown that A42 accu-
ulates within neurons in AD-vulnerable brain regions in
D (Gouras et al., 2000) and Down syndrome patients
Gyure et al., 2001) and that neurons from sporadic and
amilial AD cases contain increased A42 levels and an
ncreased A42/A40 ratio (Aoki et al., 2008).
The data in AD mouse models regarding intraneuronal
 are much more consistent and an increasing consensus
an be observed during the past years. Early intraneuronal
ccumulation has been reported in several mouse models,
ncluding APPSDLPS1M146L (Wirths et al., 2001), APPSL
S1M146L (Wirths et al., 2002), Tg2576 (Takahashi et al.,
002), 3xTg-AD (Oddo et al., 2003), 5XFAD (Oakley et al.,
006), APPArc (Knobloch et al., 2007; Lord et al., 2006),
PPT714I mice (Van Broeck et al., 2008), in APPSL
S1KIM233T, L235P mice (Casas et al., 2004) in which it was
ecently shown to correlate with neuron loss (Breyhan et al.,
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ARTICLE IN PRESSell as in TBA2 mice expressing pyroglutamate modified
3-42 (Wirths et al., 2009).
5XFAD mice expressing human APP with the Swedish,
lorida (I716V) and London mutations, together with mu-
ant PS1 (M14 6L, L28 6V) under the control of the murine
hy-1 promoter (Oakley et al., 2006) are particularly inter-
sting due to cointegration of the transgenes, enabling easy
eneration of multitransgenic AD mouse models. These
ice were generated on a B6/SJL-hybrid background and
ave been backcrossed with C57Bl6/J mice for five gener-
tions to facilitate comparison with other models which are
ostly kept on the C57Bl6 genetic background.
In the present report, we extent previous findings in the
XFAD mouse model and demonstrate that they develop an
ge-dependent motor phenotype in addition to working
emory deficits in an alternation task and reduced anxiety
evels as shown in the elevated plus maze task. Quantifica-
ion of cortical layer 5 neurons in 12 month old 5XFAD
ice by means of design-based stereology confirmed the
reviously assumed loss of neurons in this brain regions
Oakley et al., 2006; Ohno et al., 2007), however, the
verall neuron number in frontal cortex and hippocampal
A1 layer was unchanged compared with age-matched
ild-type littermates. This observation coincides with the
ccumulation of intraneuronal A peptides only in cortical
ayer 5, but not in CA1. The motor phenotype correlates
ell with abundant spinal cord pathology, including intra-




The generation of 5XFAD mice (Tg6799) has been de-
cribed previously (Oakley et al., 2006). In brief, 5XFAD
verexpress the 695 amino acids isoform of the human
myloid precursor protein (APP695) carrying the Swedish,
lorida, and London mutations under the control of the
urine Thy-1-promoter. In addition, human presenilin-1
PS1) carrying the M14 6L and L28 6V mutations mice is
xpressed also under the control of the murine Thy-1-pro-
oter. Five male mice on a C57Bl/6 x SJL genetic back-
round were obtained from Jackson Laboratories (strain:
6SJL-Tg(APPSwFlLon, PSEN1*M146L*L286V)6799Vas/J)
nd backcrossed for 5 generations to C57Bl/6J wildtype
WT) mice to obtain an incipient congenic line on a C57Bl/
J Genetic background. C57Bl6/J WT mice were used as
ontrol animals. All animals were handled according to
erman guidelines for animal care. Only female mice were
sed in the current study.
.2. Clasping test
To test clasping behavior, mice were suspended by the
ail for 30 sec to initiate the clasping phenotype. A score
as given on a scale from 0 to three, where 0 represented no m
37lasping, 1  forepaws clasping, 2  forepaws and one
ind paw clasping, and 3  all paws clasping (Miller et al.,
008). Unpaired t-test was used to compare the clasping
core between the 12 mo old 5XFAD mice and their WT
ittermates.
.3. Balance beam task
Balance and general motor function were assessed using
he balance beam task. A 1 cm dowel beam is attached to
wo support columns 44 cm above a padded surface. At
ither end of the 50 cm long beam a 9  15 cm escape
latform is attached. The animal is placed on the center of
he beam and released. Each animal is given three trials
uring a single day of testing. The time the animal remained
n the beam is recorded and the resulting latencies to fall of
ll three trials are averaged. If an animal remains on the
eam for whole 60-second trial or escapes to one of the
latforms, the maximum time of 60 sec is recorded (Aren-
ash et al., 2001; Wirths et al., 2008). The following num-
ers of animals were analyzed in this task: WT: n  11 (3
), n  13 (6 m), n  17 (9 m), n  18 (12 m); 5XFAD:
 7 (3 m), n  8 (6 m), n  10 (9 m), n  9 (12 m).
.4. String suspension task
This test was performed essentially as described previ-
usly (Wirths et al., 2008). In brief, the animals are permit-
ed to grasp the string by their forepaws and are released. A
ating system from 0 to 5 is used during the single 60-sec
rial to assess each animals’ performance in this task: 0 
nable to remain on the string; 1  hangs only by fore- or
ind paws; 2  same as for 1, but attempts to climb onto
tring; 3  sits on string and is able to hold balance; 4 
our paws and tail around string with lateral movement; 5 
scape. The following numbers of animals were analyzed in
his task: WT: n  11 (3 m), n  12 (6 m), n  17 (9 m),
 17 (12 m); 5XFAD: n  7 (3 m), n  8 (6 m), n  10
9 m), n  9 (12 m).
.5. Cross-maze
Spontaneous alternation rates were assessed using a
ross-maze built from black plastic material which had four
rms arranged in 90° position extending from a central
pace measuring 8  8 cm (arm sizes: 30 cm length, 8 cm
idth, and 15 cm height). This test is based on the same
rinciple and protocol as the Y-maze. During 10 minute test
essions, each mouse was randomly placed in one arm and
llowed to move freely through the maze. Alternation was
efined as successive entries into the four arms in overlap-
ing quadruple sets (e.g., 1, 3, 2, 4 or 2, 3, 4, 1 but not 1, 2,
, 1). The alternation percentage was calculated as the
ercentage of actual alternations to the possible number of
rm entries. To diminish odor cues, the maze was cleaned
ith 70% ethanol solution. The following number of ani-
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ARTICLE IN PRESS6 m), n  18 (9 m), n  18 (12 m); 5XFAD: n  7 (3 m),
 12 (6 m), n  10 (9 m), n  9 (12 m).
.6. Elevated plus maze
The elevated plus maze has the shape of a “” with two
lternate open and two alternate closed arms extending from
central platform. The whole maze is raised 75 cm above
he floor. The open and enclosed arms of the plus maze
enerate exploratory behavior and the avoidance of elevated
pen arms is an indication of the intensity of anxiety. Dur-
ng the test the mouse is placed onto the center field and is
llowed to explore the maze for 5 min. Anxiety can be
easured by the time spent in the open arms, with lower
nxiety levels corresponding to more time spent in open
rms (Karl et al., 2003). The percentage of the time spent
n the open arms to the overall time and the ratio of the open
rms to the total arms entries were measured using an
utomatic video tracking system (VideoMot2, TSE-Sys-
ems, Bad Homburg, Germany). The following number of
nimals was analyzed in this task: WT: n  10 (3 m),
 13 (6 m), n  12 (9 m), n  17 (12 m); 5XFAD: n 
(3 m), n  12 (6 m), n  10 (9 m), n  9 (12 m).
.7. Open Field
The open field test was used to asses both exploratory
ehavior and locomotor activity. The mice were tested us-
ng an open field box made of gray plastic with 50  50 cm
urface area and 38 cm-high walls. Monitoring was done by
n automated tracking system (VideoMot2, TSE-Systems,
ad Homburg, Germany). The behavioral parameters reg-
stered during 5-minute sessions were (i) the percentage of
ime spent in the central part (20  20 cm) versus total time
ii) total traveled distance.
.8. Immunohistochemistry on paraffin sections
Mice were transcardially perfused with 4% PFA in PBS
nd brains were carefully dissected. Post fixation was car-
ied out in 4% buffered formalin at 4 °C before the tissue
as embedded in paraffin. Immunohistochemistry was per-
ormed on 4 m sagital paraffin sections as described pre-
iously (Wirths et al., 2001). In brief, sections were depar-
ffinized in xylene and rehydrated in a series of ethanol.
fter treatment with 0.3% H2O2 in PBS to block endoge-
ous peroxidases, antigen retrieval was achieved by boiling
ections in 0.01-M citrate buffer pH 6.0, followed by
-minute incubation in 88% formic acid. Nonspecific bind-
ng sites were blocked by treatment with skim milk and fetal
alf serum in PBS, before the addition of the primary anti-
odies. The following antibodies were used: 4G8 (A17-14,
:10,000, Covance, Princeton, USA), NF200 (200 kDa-neu-
ofilament, 1:1,000, Millipore, Schwalbach, Germany), 2–48
A3pE-x, 1:100, Synaptic Systems, Göttingen, Germany,
Wirths et al., 2010)), A[N] (1:2,000, IBL, Hamburg, Ger-
any), 692 against A (1:500) and 23850 against human
PP (1:500) (Wirths et al., 2007), G2-10 (A40, 1:500, 2
38illipore, Schwalbach, Germany), ubiquitin (1:500, Dako,
lostrup, Denmark). Primary antibodies were incubated
vernight in a humid chamber at room temperature followed
y incubation with biotinylated secondary antibodies
Dako, Glostrup, Denmark). Staining was visualized using
he ABC method using a Vectastain kit (Vector Laborato-
ies, Burlingame, USA) and diaminobenzidine (DAB) as
hromogen providing a reddish-brown color. Counterstain-
ng was carried out with hematoxylin.
.9. Quantification of A plaque load
Extracellular A load (4G8, 2–48) was evaluated in
ortex and hippocampus using an Olympus BX-51 micro-
cope equipped with an Olympus DP-50 camera and the
mageJ software (V1.41, NIH, USA). Serial images of 40
agnification (hippocampus) and 100x (cortex) were cap-
ured on six sections per animal which were 30-m afar
rom each other. Using ImageJ the pictures were binarized
o 16-bit black and white images and a fixed intensity
hreshold was applied defining the DAB staining. Measure-
ents were performed for a percentaged area covered by
AB staining (Breyhan et al., 2009). The following number
f animals was used in this analysis: 5XFAD: n  4 (3 m),
 4 (6 m), n  5 (12 m). One-way ANOVA followed by
npaired t-test was used to compare age-dependent changes
n plaque load for each antibody.
.10. Quantification of neuron numbers using design-
ased stereology
Twelve months old 5xFAD (n  5) and age-matched
T mice (n  5) were anesthetized and transcardially
erfused with 4% paraformaldehyde as previously de-
cribed (Christensen et al., 2008). The brains were carefully
emoved from the skull, postfixed for 2 h and dissected.
tereological analysis was performed as previously de-
cribed (Casas et al., 2004; Schmitz et al., 2004). Briefly,
he left brain hemispheres were cryoprotected in 30% su-
rose, quickly frozen and cut frontally into entire series of
0-m thick sections on a cryostat (microM HM550,
hermo, Fisher Scientific, Walldorf, Germany). Every 10th
ection was systematically sampled, stained with cresyl
iolet and used for stereological analysis of the neuron
umber in the CA1, overall frontal cortex and fifth cortical
ayer. The hippocampal cell layer CA1 (bregma 1.22 to
3.80 mm), overall cortex (bregma 3.08–0.26 mm) and
fth cortical layer (bregma 0.1 to 3.88) were delineated
n cresyl violet-stained sections. Using a stereology work-
tation (Olympus BX51 with a motorized specimen stage
or automatic sampling, StereoInvestigator 7 [Microbright-
eld, Williston, VT, USA]) and a 100 oil lens (NA 
.35), neuronal nuclei were sampled systematic uniformly
andom using optical disector probes, and the total number
f neurons was subsequently estimated by the fractionator
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ARTICLE IN PRESShe details of the counting procedures. Unpaired t-test was
sed to compare the difference in neurons number between
2 month old 5XFAD mice and their WT littermates.
.11. Axonal degeneration
To quantify axonal degeneration, paraffin-sections of
rain and spinal cord were double-stained for neurofila-
ents (NF200, DAB) and A (4G8, Histogreen) and the
umber of nonplaque-associated spheroids was quantified in
oth pons (sagittal sections, starting at bregma 0.36 mm)
Paxinos and Franklin, 2001) and spinal cord (cross-sec-
ions of gray matter of the medial part of the cervical spinal
ord with a random start). Serial images of 100 magnifi-
ation were captured on six sections per animal which were
0-m afar from each other. For quantification, the meander
can option of StereoInvestigator 7 (Microbrightfield, Wil-
iston, VT, USA) was used. The following number of ani-
als was used in this analysis: 5XFAD: n  4 (3 m), n 
(6 m), n  5 (12 m). One-way ANOVA followed by
npaired t-test was used to compare age-dependent changes
n axonal spheroids.
.12. Statistical analysis
Differences between groups were tested with either one-
ay or two-way analysis of variance (ANOVA) followed
y Bonferroni post-tests or unpaired t-tests. All data were
iven as mean  SEM. Significance levels were given as
ollows: ***p  0.001; **p  0.01; *p  0.05. All calcu-
ations were performed using GraphPad Prism version 4.03
or Windows (GraphPad Software, San Diego, USA).
. Results
.1. Phenotypical characterization
5XFAD mice showed a reduced body weight in compar-
son with their WT littermates. Analysis by Two-way
NOVA revealed a significant genotype effect starting at 9
onths of age (p  0.05, Fig. 1A). In addition, 5XFAD
ice showed a characteristic clasping phenotype presented
y an unusual simultaneous retraction of both fore- and hind
aws. Quantitative measurement of this behavior at 12 mo
f age, by suspending the animals by their tail and evalu-
ting the clasping score, revealed a significant increase in
able 1
etails of the counting procedure used to evaluate neuron numbers
egion counted Obj. Av. No. sections B (
A1 pyramidal neurons 100 9 196
rontal cortex 100 9 625
ortex layer 5 neurons 100 11 625
v. no sections, average number of sections used; B and H, base and height
fter histological processing;  OD, average sum of optical disectors used; 
f error of the estimated total number of neurons.he clasping score in the 5XFAD mice (p  0.001, Fig. 1B). F
39Sensory-motor abilities were analyzed using two differ-
nt tasks. The balance beam measures the ability of the mice
o remain on a thin wooden dowel. Whereas 3 and 6 mo old
XFAD mice did not show any significant impairment in
his task compared with their WT littermates, 9 mo old
XFAD mice started to show a decreased latency to fall
p  0.05) which became more significant by 12 mo of age
p  0.001, Fig. 1C). The second sensory-motor task used
as the string suspension paradigm which measures the
bility of a mouse to hold on a wire using its forepaws.
XFAD mice showed poorer performance compared with
he WT control mice at both 9 and 12 mo of age (both p 
.001), whereas younger mice at 3 and 6 mo of age did not
how impairment (p  0.05, Fig. 1D).
.2. Age-dependent working memory impairment in
XFAD mice
The cross maze was used to measure the alternation as an
ndicator of spatial working memory impairment. Analysis
f the alternation percentage did not show any noticeable
roblems at the age of 3 mo (p  0.05), however, it revealed
significant impairment in the working memory in 6 mo old
XFAD mice which became more significant in 9 and 12
o old mice (6 m, p  0.05; 9 m, p  0.01; 12 m, p  0.01)
Fig. 1E). The reduced alternation percentage was obviously
ot due to a decrease in overall explorative behavior as
XFAD mice showed the same number of total arm entries
n comparison with their WT littermates at any analyzed
ime point (Fig. 1F).
.3. Age-dependent increase of plaque-associated A in
ortex and hippocampus
Sagittal brain sections of 5XFAD mice at 3, 6, and 12 mo
f age (Fig. 2) were stained with two different A antibod-
es detecting either a central A epitope (4G8, A17-24) or
-terminal truncated A peptides starting with a pyroglu-
amate at Position 3 (2–48; AN3pE). Plaque load was
uantified in the frontal cortex and the hippocampus as
escribed earlier (Christensen et al., 2008) (Fig. 2A–F).
sing the 4G8 antibody a continuous increase in A plaque
oad was noted in both cortex (3 m: 1.89  0.57%; 6 m:
.23  1.09%; 12 m: 9.72  0.91%) and hippocampus (3
: 0.78  0.11%; 6 m: 3.32  0.34%; 12 m: 8.03  1.04%,
H (m) t (m)  OD  Q CEpred[n]
5 10.4 301.3 477.8 0.046
6 11.7 219.3 348.2 0.055
6 10.7 135 228.8 0.068
ptical disectors; Obj, objective used t, measured average section thickness
erage number of neurons counted; CEpred[n], average predicted coefficientm2)
of the o
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ARTICLE IN PRESS–48 antibody detecting pyroglutamate-A, which also
hows a continuous significant increase in both cortex (3 m:
.09  0.03%; 6 m: 0.83  0.1%; 12 m: 3.53  0.88%) and
ippocampus (3 m: 0.05  0.03%; 6 m: 1.64  0.28%;
2 m: 3.1  0.47%, Fig. 2D–F).
.4. Decreased anxiety levels but normal locomotor
ehavior in 5XFAD mice
The elevated plus maze was used to study anxiety levels
ig. 1. 5XFAD mice show age-dependent changes in body weight (A).
nalysis of clasping behavior showed a significant difference between
XFAD mice and WT littermates at 12 months of age (B). Analysis of motor
erformance revealed deficits in the balance beam (C) and the string suspen-
ion task (D) starting at 9 months of age. Evaluation of working memory using
he cross-maze demonstrated reduced alternation rates starting from 6 months
f age. The dotted line represents chance level (E). This reduction is not due
educed explorative behavior because there was no difference in the total arm
ntries between the 5XFAD and their WT littermates (F). All error bars
epresent SEM ***p  0.001, **p  0.01; *p  0.05.n 5XFAD mice at 3, 6, 9, and 12 mo of age. 5XFAD mice I
40howed an age-dependent decreased anxiety phenotype
hich was indicated by spending more time in the open
rms starting from 6 mo of age (6, 9, 12 m: p  0.001) (Fig.
C). This was confirmed by calculating the ratio of open
rm entries to total arm entries which revealed significant
igher ratios in 6, 9, and 12 mo old 5XFAD mice compared
ith WT animals (p  0.001) (Fig. 3D). In addition, ex-
loratory and spontaneous locomotor activity of the 5XFAD
ice was compared with WT mice at 9 and 12 mo of age in
he open-field paradigm. No significant difference in the
overed distance (Fig. 3F) or the speed (not shown) between
T and 5XFAD mice was noted during the 5 min trial (p 
.05). Interestingly, 12 mo old 5XFAD mice spent more
ime in the center of the maze in comparison with their WT
ittermates (p  0.001) reflecting reduced anxiety and con-
rming the findings from the elevated plus maze experiment
Fig. 3E).
.5. No overt hippocampal and cortical neuron loss in 12
onth old 5XFAD mice
The number of neurons was quantified in the CA1 region
f the hippocampus and the frontal cortex in 12 mo old
XFAD and WT mice by design-based stereology. CA1 was
efined from bregma 1.22 to 3.80 and the frontal cortex
as defined from bregma 3.08 to 0.26. Stereological quan-
ification of the pyramidal neurons of the CA1 layer showed
o significant difference between the numbers of neurons of
T (261,654  16,594) and 5XFAD mice (221,848 
2,088) (Fig. 4A–C). The same holds true for the neuron
umber of the frontal cortex where no significant difference
etween WT (2,031,081  301,914) and 5XFAD (1,867,068 
54,977) mice could be established (Fig. 4D–F).
.6. Loss of neurons in cortical Layer 5 correlates with
ntraneuronal A accumulation
A loss of neurons in the Layer 5 of the cortex has been
reviously assumed, however, quantitative data were lack-
ng so far (Oakley et al., 2006; Ohno et al., 2007). There-
ore, cortical layer 5 neurons were counted in 12 mo old
XFAD and WT mice by design-based stereology and a
ignificant loss of these neurons was found in 5XFAD
320,896  44,205) compared with WT mice (518,451 
0,133; p  0.01) (Fig. 4G–I). Qualitative immunostainings
sing an antiserum against human APP revealed strong
mmunoreactivity in deep cortical layers (Fig. 5A–B), as
ell as in the CA1–CA3 regions of the hippocampal for-
ation (Fig. 5F-G). Staining with antibodies detecting var-
ous forms of A peptides revealed strong intraneuronal
mmunoreactivity in cortical layer 5 neurons in 3 mo old
XFAD mice (Fig. 5C–E), which decreased with aging and
as almost absent in 12 mo old 5XFAD mice (not shown).
o intraneuronal A could be detected in the hippocampal
ormation of 3, 6, or 12 mo old 5XFAD mice (Fig. 5H).
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ARTICLE IN PRESSerous plaque-associated, as well as plaque-independent
40-positive axonal swellings could be detected in three-,
ix- and 12 month old 5XFAD mice. In addition, A40-
ositive neuritic processes were detected at later stages (Fig.
I–K).
.7. A pathology in the spinal cord of 5XFAD mice
As human APP is expressed under the control of the
euron-specific murine Thy-1-promoter, it is present in both
rain and spinal cord. Using an antiserum against human
PP, abundant APP immunoreactivity was detected in spi-
al cord motor neurons, as well as in neuronal processes of
he dorsal column (Fig. 6A,B,E). Quantification of extracel-
ular A plaques in the spinal cord revealed a significant
ge-dependent increase (Fig. 6D). In addition, intraneuronal
 accumulation in spinal cord motor neurons could be
emonstrated using different A antibodies (Fig. 6C,F–H).
.8. Axonal degeneration in 5XFAD mice
Staining with antibodies against APP, ubiquitin (not
hown) and NF200 (a neurofilament subunit) disclosed
ig. 2. Plaque-load quantification in cortex and hippocampus showed an age
an A (4G8, A–C) and pyroglutamate-modified-A (2–48, D–F). Repres
**p  0.001, **p  0.01; *p  0.05. Scale bar: 200 m.arked axonal swellings in the brain and the spinal cord, n
41ainly decorating extracellular plaques in the form of dys-
rophic neurites (Fig. 5B, 7E). However, larger axonal sphe-
oids were also present independent from plaques. These ax-
nal dilatations were present in many brain regions already at
mo of age, such as cortex, hippocampus, midbrain, and
indbrain regions like medulla or pons which increased in an
ge-dependent manner. To examine whether the motor deficits
orrelate with the axonal defects, a detailed analysis of the
pinal cord revealed that the axonal dilatations were present
ainly in the gray matter in addition to some spheroids located
t the border of gray and white matter.
To quantify plaque-independent axonal spheroids, dou-
le stainings using 4G8 and NF200 were performed. Quan-
ification was carried out in the pons (Fig. 7A–C) and the
ray matter of the spinal cord (Fig. 7E–G). One-way
NOVA followed by unpaired t-test revealed a significant
ncrease in plaque independent axonal spheroids between 3
nd 6 mo of age in the pons (p 0.05), as well as the spinal
ord (p  0.01), in which a further significant increase
etween 6 and 12 mo of age was detected (p  0.001),
hile in the pons no significant additional increase was
dent increase from 3 to 6-to 12-month-old mice using antibodies that detect
e images of 6-month-old mice were shown. All error bars represent SEM-depen
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ARTICLE IN PRESS. Discussion
The 5XFAD mouse model represents a double transgenic
PP/PS1 mouse line coexpressing five familial Alzheimer
isease (5XFAD) mutations that are inherited together and
ead to accelerated plaque formation and increased A42
evels. It was previously described as one of the few AD
odels showing several AD hallmarks, including neuron
oss (Oakley et al., 2006). The aim of the present work was
o perform a detailed characterization of the 5XFAD mouse
odel on a C57/BLJ genetic background, providing a de-
ailed neuropathological, behavioral and stereological anal-
sis in an age-dependent manner.
The 5XFAD model has been reported to develop plaque
eposition starting already at the age of 2 mo (Oakley et al.,
ig. 3. Elevated-plus maze revealed reduced anxiety in 5XFAD mice. An
xample of the recorded path of WT mice (A) and 5XFAD mice (B) in the
levated-plus maze. The time spent in the open arms (o) was significantly
igher in 5XFAD mice compared with their WT littermates starting from
months of age (C). The ratio of open arm visits to total visits showed the
ame pattern (D). 12-months-old 5XFAD mice spent more time in the
enter of the open field in mice compared with WT littermates (E).
owever, there was no difference in the total traveled distance between
XFAD and WT mice. All error bars represent SEM ***p  0.001, **p 
.01; *p  0.05.006). Two pools of A plaques were analyzed at different m
42ime points which were either total A (detected by 4G8)
nd pyroglutamate-modified A (detected by 2–48). Both
otal A and the pyroglutamate-modified A pools showed
continuous increase with age in cortex and hippocampus.
he importance of pyroglutamate-modified A arises from
ts characteristics, such as higher aggregation propensity
He and Barrow, 1999; Schilling et al., 2006), stronger
ydrophobicity (Kuo et al., 1997), and increased toxicity
ompared with full-length A (Russo et al., 2002) making it
potential target to treat AD. 5XFAD mice display a pro-
ressive neurological phenotype which is characterized by
rowth retardation, an abnormal clasping phenotype and
otor impairment. 12-Months-old 5XFAD mice showed an
bnormal extension reflex by retracting hind- and fore-paws
imultaneously when suspended by the tail. This abnormal
lasping-pattern has been described in several AD models,
ncluding mice transgenic for human four-repeat Tau
Probst et al., 2000), human apolipoprotein E4 (ApoE4)
Tesseur et al., 2000), as well as APP/PS1KI (Wirths et al.,
007; Wirths et al., 2008), which all showed signs of ax-
nopathy. In agreement with the clasping behavior, the
otor phenotype started to become prominent in 5XFAD
ice at 9 mo of age when tested in the balance beam and
tring suspension tasks. Motor impairments, including ri-
idity and impairments in gait or posture have also been
epeatedly reported in AD patients (O’Keeffe et al., 1996;
ettersson et al., 2005; Scarmeas et al., 2004; Scarmeas et
l., 2005; Wirths and Bayer, 2008), as well as other APP
ransgenic mouse models, including APP single transgenic
ice (Le Cudennec et al., 2008; Lee et al., 2004), APP/PS1
Ewers et al., 2006) or APP/PS1KI mice (Wirths et al.,
008). The assessment of motor impairment is a highly
elevant issue, as some reference memory tasks like the
orris water maze are severely influenced by any distur-
ance in motor performance, leading to erroneous results.
The motor deficits seen in the 5XFAD mice correlate
ith the formation of axonal spheroids present in the brain
nd spinal cord, which represents the most prominent his-
ological evidence of central nervous system axonopathy in
hese mice. Axonal swellings have been previously reported
n other APP transgenic mouse models to a variable extent
Stokin et al., 2005; Wirths et al., 2006; Wirths et al., 2007)
nd are also present in Tau (Probst et al., 2000; Spittaels et
l., 1999) or ApoE-based (Tesseur et al., 2000) AD trans-
enic mouse models. The presence of intraneuronal A
ithin spinal cord motor neurons might lead to axonal
ransport impairment, as it has been shown that A42 ac-
umulates in lumbar motor neurons of patients suffering
rom amyotrophic lateral sclerosis (ALS) (Calingasan et al.,
005), a disease in which axonal transport deficits are
learly implicated (reviewed in (Chevalier-Larsen and Hol-
baur, 2006)). We hypothesize that the accumulation of
ntraneuronal A in motor neurons in the 5XFAD mouse
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ARTICLE IN PRESSepresented by deficits in motor performance and increased
xonal spheroid formation.
The spatial working memory was analyzed to recapitu-
ate if the previously published impairment in the Y-maze
ask (Oakley et al., 2006) is still detectable in mice kept on
different genetic background. In the present study, the
ross-maze was used, which is based on the same principle
s the Y-maze task. The only difference between the two
azes is that the cross-maze presents a higher level of
omplexity because it has four arms instead of the three
rms in the Y-maze which makes it more sensitive to depict
emory impairments. In agreement with previous results
Oakley et al., 2006), 5XFAD mice showed a reduced al-
ernation percentage in the cross maze starting from 6
onths of age. This reduction was obviously not due to
ecreased motor activity because the 5XFAD mice showed
comparable number of arm entries as their WT littermates.
educed working memory levels that decline with age have
een demonstrated in a variety of AD transgenic mouse
odels (Chapman et al., 1999; Duyckaerts et al., 2008;
ovasic et al., 2005; Wirths et al., 2008). 5XFAD mice have
een previously demonstrated to exhibit deficits in memory
ig. 4. Quantification of neurons in the CA1 (A–C), the overall frontal cor
ice at 12 months of age. While no difference in the number of neurons
oted in the fifth cortical layer of 5XFAD mice compared with WT (I). A
0 m.onsolidation, demonstrated by significantly lower levels of 5
43ontextual freezing starting at the age of 5–6 mo (Devi and
hno, 2010; Ohno et al., 2006; Ohno, 2009). In good
greement, age-dependent impairments of basal synaptic
ransmission in hippocampal slices of 5XFAD mice have
een described. At 6 mo of age, significant reductions in
ynaptic transmission were detected, whereas 4 mo old
XFAD mice showed no impairment (Kimura and Ohno,
009).
In addition, 5XFAD mice demonstrated reduced anxiety
y spending more time in the open arms of the elevated
lus-maze in comparison with their WT littermates starting
rom an early age (6 mo old) which further increased in an
ge-dependent manner. Various AD mouse models showed
ifferent anxiety profiles. Mouse models like Tg2576, PS1-
246E or bigenic APPswe  PS1/DeltaE9 and APP/PS1KI
ice have shown reduced anxiety (Faure et al., 2009; La-
onde et al., 2003a; Lalonde et al., 2003b; Lalonde et al.,
005), whereas other AD mouse models, such as APP23 did
ot demonstrate any change in their anxiety level (Lalonde
t al., 2002). Analysis of anxiety, exploration and locomotor
ctivity in the open field paradigm confirmed the reduction
n anxiety detected using elevated plus maze because the
F) and the fifth cortical layer (G–I) of 5XFAD (B,E,H) and WT (A,D,G)
(C) or the frontal cortex was detected (F), a neuron loss of 	 38% was
bars represent s.e.m. **p  0.01. Scale bars: (A,B,D,E) 200 m; (D,H)tex (D–
in CA1
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ARTICLE IN PRESSared with their WT littermates. In contrast, locomotor
ehavior did not seem to be affected because there was no
ifference detected in the speed or the traveled distance
uring the 5 min of testing.
ig. 5. Immunostaining for APP and intraneuronal A in the cortex (A–E,I
n the fifth cortical layer (A,B) and the CA1 region (F,G). However, sta
ntraneuronal A accumulation (arrows) was limited to the fifth cortica
laque-associated axonal spheroids (arrowhead) in 3- (I), 6- (J) and 12 m
large arrows) and A40-positive neuritic processes (small arrows) were
ig. 6. APP and A staining in the spinal cord of 5XFAD mice. Staining
months of age (A,B,E). 4G8 antibody showed plaque pathology and int
gainst A, such as 692 (G) and A[N] (H) confirmed the finding of intra
laque load demonstrated a continuous increase with age (D). All error ba
m; (E–H) 20 m.
44Neuron loss in cortical layer 5 neurons has been previ-
usly observed in 5XFAD mice; however, no quantitative
ata on the extent was available (Oakley et al., 2006).
ompared with age-matched WT mice, a significant neuron
CA1 (F–H). Staining against APP revealed comparable expression levels
ith G2-10 (A40, C), A[N] (A1-x, D), 692 (A, E) showed that the
but not the CA1 pyramidal layer (A[N]; H). A40 was detected in
d 5XFAD mice. In addition plaque-independent A40-positive spheroids
. Scale bars: (A): 200 m, (B–K) 50 m.
t APP revealed expression in motor neurons of the spinal cord already at
nal A as early as 3 months of age (C,F). Staining with other antibodies
al A in spinal cord motor neurons. In addition, quantification of the A
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ARTICLE IN PRESSoss could be detected in layer 5 neurons of the cortex in 12
o old 5XFAD mice in the present study. These neurons
xpress human APP and accumulate considerable amounts
f A peptides already at the age of 3 mo. On the contrary,
o neuron loss could be detected in the CA1 layer of the
ippocampus which shows comparable levels of transgenic
PP expression, however, without intraneuronal A accu-
ulation. This confirms previous findings in APP/PS1KI
ice, where neuron loss only occurs in brain regions show-
ng intraneuronal A accumulation, like frontal cortex, CA1
r distinct cholinergic brain stem nuclei. In the thalamus or
he striatum, representing regions where only extracellular
laques are detectable, no neuron loss could be demon-
trated (Breyhan et al., 2009; Casas et al., 2004; Christensen
t al., 2008; Christensen et al., 2010), arguing against a
ig. 7. Double immunostaining showing A in blue using antibody 4G8
ogether with visualization of fibers in reddish-brown using NF-200 in the
ons (Z-D) and the spinal cord (E–H) of 5XFAD mice. Axonal swelling are
hown in 6- (A,B,E,F) and 12 month old (C,G) mice. Quantification of
laque-independent-axonal swellings revealed a significant increase from 3
o 6 months of age in the pons (D), while it showed a continuous age-
ependent increase in the spinal cord (H). All error bars represent SEM
**p  0.001, **p  0.01; *p  0.05. Scale bars: (A,E) 200 m;
B,C,F,G) 50 m.ignificant role of extracellular plaques in terms of A S
45oxicity. In good agreement, only a weak correlation be-
ween plaque density and hippocampus-dependent memory
as been found in 8 mo old 5XFAD mice (Kaczorowski et
l., 2009). Very recently, a new APP transgenic mouse
odel has been described harboring the E693
 mutation.
hese mice do not show any extracellular amyloid deposits
ven at 24 mo of age, but reveal CA3 neuron loss at this
ime point which is preceded by intraneuronal A oligomer
ccumulation (Tomiyama et al., 2010). Taken together, the
ecent data from APP/PS1KI, 5XFAD and APP E693

ice indicate that there is compelling evidence for a central
ole of intraneuronal A accumulation leading to neuron
oss in APP transgenic mouse models of AD.
In addition to A peptides located in somatodendritic
ompartments, A was also detected in axonal spheroids
nd neuritic processes, adding further evidence to its intra-
euronal localization. This corroborates previous data in
PP/PS1KI mice (Wirths et al., 2007) and supports the idea
hat A might be produced or released within axons (Kamal
t al., 2001; Zhu et al., 2005). It has also been hypothesized
hat axonal swellings precede and participate in amyloid
laque formation, probably because of focally increased A
ecretion or lysis of swellings enriched in A peptides
Stokin et al., 2005).
In conclusion, the 5XFAD mouse model recapitulates a
ariety of AD hallmarks, including working memory im-
airment, reduced anxiety corresponding to disinhibitory
endencies seen in AD patients, extensive extracellular
laque formation and selective neuron loss, making it a
ighly valuable research model. As neurofibrillary tangle
ormation is lacking, this model might represent a model for
he “plaque predominant” type of AD which has been pre-
iously described in various autopsy series (Duyckaerts et
l., 2009; Hansen et al., 1993; Tiraboschi et al., 2004).
owever, as intraneuronal A plays a significant role in
erms of the pathological alterations characterizing this
odel, it might be defined as an “amyloid-predominant”
odel of AD.
isclosure statement
Animal studies were performed with the approval of the
ocal Research Ethics Committee in accordance with na-
ional and international guidelines. All efforts were made to
inimize animal suffering and the number of animals used.
he authors have no financial, personal, or other conflicts of
nterest to disclose.
cknowledgements
The expert technical assistance of Petra Tucholla is
ratefully acknowledged. We thank Gerd Multhaup for the
enerous gift of 23850 and 692 antibodies. This work was
upported by The European Commission, Marie Curie Early








































11S. Jawhar et al. / Neurobiology of Aging xx (2010) xxx
ARTICLE IN PRESSeimer Ph.D. Graduate School, Alzheimer Forschung Ini-
iative e.V. (to O.W.), and the Competence Network De-
enerative Dementias of the German Federal Ministry of
ducation (grant no. 01 GI 0718, to T.A.B.).
eferences
oki, M., Volkmann, I., Tjernberg, L.O., Winblad, B., Bogdanovic, N.,
2008. Amyloid beta-peptide levels in laser capture microdissected
cornu ammonis 1 pyramidal neurons of Alzheimer’s brain. Neuroreport
19, 1085–1089.
rendash, G.W., Gordon, M.N., Diamond, D.M., Austin, L.A., Hatcher,
J.M., Jantzen, P., DiCarlo, G., Wilcock, D., Morgan, D., 2001. Behav-
ioral assessment of Alzheimer’s transgenic mice following long-term
Abeta vaccination: task specificity and correlations between Abeta
deposition and spatial memory. DNA Cell Biol. 20, 737–744.
reyhan, H., Wirths, O., Duan, K., Marcello, A., Rettig, J., Bayer, T.A.,
2009. APP/PS1KI bigenic mice develop early synaptic deficits and
hippocampus atrophy. Acta Neuropathol. 117, 677–685.
alingasan, N.Y., Chen, J., Kiaei, M., Beal, M.F., 2005. beta-amyloid 42
accumulation in the lumbar spinal cord motor neurons of amyotrophic
lateral sclerosis patients. Neurobiol. Dis. 19, 340–347.
asas, C., Sergeant, N., Itier, J.M., Blanchard, V., Wirths, O., van der
Kolk, N., Vingtdeux, V., van de Steeg, E., Ret, G., Canton, T., Dro-
becq, H., Clark, A., Bonici, B., Delacourte, A., Benavides, J., Schmitz,
C., Tremp, G., Bayer, T.A., Benoit, P., Pradier, L., 2004. Massive p.
CA1/2 neuronal loss with intraneuronal and N-terminal truncated
Abeta42 accumulation in a novel Alzheimer transgenic model. Am. J.
Pathol. 165(4), 1289–1300.
hapman, P.F., White, G.L., Jones, M.W., Cooper-Blacketer, D., Marshall,
V.J., Irizarry, M., Younkin, L., Good, M.A., Bliss, T.V., Hyman, B.T.,
Younkin, S.G., Hsiao, K.K., 1999. Impaired synaptic plasticity and
learning in aged amyloid precursor protein transgenic mice. Nat. Neu-
rosci. 2, 271–276.
hevalier-Larsen, E., Holzbaur, E.L., 2006. Axonal transport and neuro-
degenerative disease. Biochim. Biophys. Acta 1762, 1094–1108.
hristensen, D.Z., Bayer, T.A., Wirths, O., 2010. Intracellular Abeta trig-
gers neuron loss in the cholinergic system of the APP/PS1KI mouse
model of Alzheimer’s disease. Neurobiol. Aging 31, 1153–1163.
hristensen, D.Z., Kraus, S.L., Flohr, A., Cotel, M.C., Wirths, O., Bayer,
T.A., 2008. Transient intraneuronal Abeta rather than extracellular
plaque pathology correlates with neuron loss in the frontal cortex of
APP/PS1KI mice. Acta Neuropathol. 116, 647–655.
evi, L., Ohno, M., 2010. Genetic reductions of beta-site amyloid precur-
sor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment
of conditioned taste aversion memory in 5XFAD Alzheimer’s disease
model mice. Eur. J. Neurosci. 31, 110–118.
uyckaerts, C., Delatour, B., Potier, M.C., 2009. Classification and basic
pathology of Alzheimer disease. Acta Neuropathol. 118, 5–36.
uyckaerts, C., Potier, M.C., Delatour, B., 2008. Alzheimer disease mod-
els and human neuropathology: similarities and differences. Acta Neu-
ropathol. 115, 5–38.
wers, M., Morgan, D.G., Gordon, M.N., Woodruff-Pak, D.S., 2006.
Associative and motor learning in 12 month old transgenic APPPS1
mice. Neurobiol. Aging 27, 1118–1128.
aure, A., Verret, L., Bozon, B., El Tannir El Tayara, N., Ly, M., Kober,
F., Dhenain, M., Rampon, C., Delatour, B., 2009. Impaired neurogen-
esis, neuronal loss, and brain functional deficits in the APPxPS1-Ki
mouse model of Alzheimer’s disease. Neurobiol. Aging Apr 22. [Epub
ahead of print].
ouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F.,
Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., Greengard,
P., Relkin, N.R., 2000. Intraneuronal Abeta42 accumulation in human
brain. Am. J. Pathol. 156, 15–20.
46yure, K.A., Durham, R., Stewart, W.F., Smialek, J.E., Troncoso, J.C.,
2001. Intraneuronal abeta-amyloid precedes development of amyloid
plaques in Down syndrome. Arch. Pathol. Lab. Med. 125, 489–492.
ansen, L.A., Masliah, E., Galasko, D., Terry, R.D., 1993. Plaque-only
Alzheimer disease is usually the lewy body variant, and vice versa.
J. Neuropathol. Exp. Neurol. 52, 648–654.
e, W., Barrow, C.J., 1999. The A beta 3-pyroglutamyl and 11-pyroglu-
tamyl peptides found in senile plaque have greater beta-sheet forming
and aggregation propensities in vitro than full-length A beta. Biochem-
istry 38, 10871–1087.
aczorowski, C.C., Sametsky, E., Shah, S., Vassar, R., Disterhoft, J.F.,
2009. Mechanisms underlying basal and learning-related intrinsic ex-
citability in a mouse model of Alzheimer’s disease. Neurobiol. Aging
Oct 13. [Epub ahead of print].
amal, A., Almenar-Queralt, A., LeBlanc, J.F., Roberts, E.A., Goldstein,
L.S., 2001. Kinesin-mediated axonal transport of a membrane compart-
ment containing beta-secretase and presenilin-1 requires APP. Nature
414, 643–648.
arl, T., Pabst, R., von Horsten, S., 2003. Behavioral phenotyping of mice
in pharmacological and toxicological research. Exp. Toxicol. Pathol.
55, 69–83.
imura, R., Ohno, M., 2009. Impairments in remote memory stabilization
precede hippocampal synaptic and cognitive failures in 5XFAD Alz-
heimer mouse model. Neurobiol. Dis. 33, 229–235.
nobloch, M., Konietzko, U., Krebs, D.C., Nitsch, R.M., 2007. Intracel-
lular Abeta and cognitive deficits precede beta-amyloid deposition in
transgenic arcAbeta mice. Neurobiol. Aging, 28, 1297–1306.
uo, Y.M., Emmerling, M.R., Woods, A.S., Cotter, R.J., Roher, A.E.,
1997. Isolation, chemical characterization, and quantitation of A beta
3-pyroglutamyl peptide from neuritic plaques and vascular amyloid
deposits. Biochem. Biophys. Res. Commun. 237, 188–191.
alonde, R., Dumont, M., Staufenbiel, M., Sturchler-Pierrat, C., Strazielle,
C., 2002. Spatial learning, exploration, anxiety, and motor coordination
in female APP23 transgenic mice with the Swedish mutation. Brain
Res. 956, 36–44.
alonde, R., Kim, H.D., Maxwell, J.A., Fukuchi, K., 2005. Exploratory
activity and spatial learning in 12 month old APP(695)SWE/coPS1/
DeltaE9 mice with amyloid plaques. Neurosci Lett 390(2), 87–92.
alonde, R., Lewis, T.L., Strazielle, C., Kim, H., Fukuchi, K., 2003a.
Transgenic mice expressing the betaAPP695SWE mutation: effects on
exploratory activity, anxiety, and motor coordination. Brain Res. 977,
38–45.
alonde, R., Qian, S., Strazielle, C., 2003b. Transgenic mice expressing the
PS1-A246E mutation: effects on spatial learning, exploration, anxiety,
and motor coordination. Behav. Brain Res. 138, 71–79.
e Cudennec, C., Faure, A., Ly, M., Delatour, B., 2008. One-year longi-
tudinal evaluation of sensorimotor functions in APP751SL transgenic
mice. Genes Brain Behav. 7 suppl 1, 83–91.
ee, K.W., Lee, S.H., Kim, H., Song, J.S., Yang, S.D., Paik, S.G., Han,
P.L., 2004. Progressive cognitive impairment and anxiety induction in
the absence of plaque deposition in C57BL/6 inbred mice expressing
transgenic amyloid precursor protein. J. Neurosci. Res. 76, 572–580.
ord, A., Kalimo, H., Eckman, C., Zhang, X.Q., Lannfelt, L., Nilsson,
L.N., 2006. The Arctic Alzheimer mutation facilitates early intraneu-
ronal Abeta aggregation and senile plaque formation in transgenic
mice. Neurobiol. Aging 27, 67–77.
ovasic, L., Bauschke, H., Janus, C., 2005. Working memory impairment
in a transgenic amyloid precursor protein TgCRND8 mouse model of
Alzheimer’s disease. Genes Brain Behav. 4, 197–208.
’Keeffe, S.T., Kazeem, H., Philpott, R.M., Playfer, J.R., Gosney, M.,
Lye, M., 1996. Gait disturbance in Alzheimer’s disease: a clinical
study. Age Ageing 25, 313–316.
akley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-
Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R.,
Vassar, R., 2006. Intraneuronal beta-amyloid aggregates, neurodegen-
































12 S. Jawhar et al. / Neurobiology of Aging xx (2010) xxx
ARTICLE IN PRESSmer’s disease mutations: potential factors in amyloid plaque formation.
J. Neurosci. 26, 10129–10140.
ddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed,
R., Metherate, R., Mattson, M.P., Akbari, Y., LaFerla, F.M., 2003.
Triple-transgenic model of Alzheimer’s disease with plaques and tan-
gles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409–
421.
hno, M., 2009. Failures to reconsolidate memory in a mouse model of
Alzheimer’s disease. Neurobiol. Learn. Mem. 92, 455–459.
hno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W.L.,
Vassar, R., Disterhoft, J.F., 2006. Temporal memory deficits in Alz-
heimer’s mouse models: rescue by genetic deletion of BACE1. Eur.
J. Neurosci. 23, 251–260.
hno, M., Cole, S.L., Yasvoina, M., Zhao, J., Citron, M., Berry, R.,
Disterhoft, J.F., Vassar, R., 2007. BACE1 gene deletion prevents neu-
ron loss and memory deficits in 5XFAD APP/PS1 transgenic mice.
Neurobiol. Dis. 26, 134–145.
axinos, G., Franklin, K.B.J., 2001. The Mouse Brain in Stereotaxic
Coordinates, 2nd Ed. Academic Press.
ettersson, A.F., Olsson, E., Wahlund, L.O., 2005. Motor function in
subjects with mild cognitive impairment and early Alzheimer’s disease.
Dement. Geriatr. Cogn. Disord. 19, 299–304.
robst, A., Gotz, J., Wiederhold, K.H., Tolnay, M., Mistl, C., Jaton, A.L.,
Hong, M., Ishihara, T., Lee, V.M., Trojanowski, J.Q., Jakes, R.,
Crowther, R.A., Spillantini, M.G., Burki, K., Goedert, M., 2000. Ax-
onopathy and amyotrophy in mice transgenic for human four-repeat tau
protein. Acta Neuropathol. 99, 469–481.
usso, C., Violani, E., Saxlis, S., Venezia, V., Dolcini, V., Damonte, G.,
Benatti, U., D’Arrigo, C., Patrone, E., Carlo, P., Schettini, G., 2002.
Pyroglutamate-modified amyloid beta-peptides—AbetaN3(pE)—strongly
affect cultured neuron and astrocyte survival. J. Neurochem. 82,
1480–1489.
carmeas, N., Albert, M., Brandt, J., Blacker, D., Hadjigeorgiou, G.,
Papadimitriou, A., Dubois, B., Sarazin, M., Wegesin, D., Marder, K.,
Bell, K., Honig, L., Stern, Y., 2005. Motor signs predict poor outcomes
in Alzheimer disease. Neurology 64, 1696–1703.
carmeas, N., Hadjigeorgiou, G.M., Papadimitriou, A., Dubois, B., Sara-
zin, M., Brandt, J., Albert, M., Marder, K., Bell, K., Honig, L.S.,
Wegesin, D., Stern, Y., 2004. Motor signs during the course of Alz-
heimer disease. Neurology 63, 975–982.
chilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Bohm, G.,
Demuth, H.U., 2006. On the seeding and oligomerization of pGlu-
amyloid peptides (in vitro). Biochemistry 45, 12393–12399.
chmitz, C., Hof, P.R., 2005. Design-based stereology in neuroscience.
Neuroscience 130, 813–831.
chmitz, C., Rutten, B.P., Pielen, A., Schafer, S., Wirths, O., Tremp, G.,
Czech, C., Blanchard, V., Multhaup, G., Rezaie, P., Korr, H., Stein-
busch, H.W., Pradier, L., Bayer, T.A., 2004. Hippocampal neuron loss
exceeds amyloid plaque load in a transgenic mouse model of Alzhei-
mer’s disease. Am. J. Pathol. 164, 1495–1502.
pittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandez-
ande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel,
A., Loos, R., Van Leuven, F., 1999. Prominent axonopathy in the brain
and spinal cord of transgenic mice overexpressing four-repeat human
tau protein. Am. J. Pathol. 155, 2153–2165.
tokin, G.B., Lillo, C., Falzone, T.L., Brusch, R.G., Rockenstein, E.,
Mount, S.L., Raman, R., Davies, P., Masliah, E., Williams, D.S.,
Goldstein, L.S., 2005. Axonopathy and transport deficits early in the
pathogenesis of Alzheimer’s disease. Science 307, 1282–1288.
akahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi,
H., Beal, M.F., Xu, H., Greengard, P., Gouras, G.K., 2002. Intraneu-
47ronal Alzheimer abeta42 accumulates in multivesicular bodies and is
associated with synaptic pathology. Am. J. Pathol. 161, 1869–1879.
esseur, I., Van Dorpe, J., Bruynseels, K., Bronfman, F., Sciot, R., Van
Lommel, A., Van Leuven, F., 2000. Prominent axonopathy and dis-
ruption of axonal transport in transgenic mice expressing human apo-
lipoprotein E4 in neurons of brain and spinal cord. Am. J. Pathol. 157,
1495–1510.
iraboschi, P., Sabbagh, M.N., Hansen, L.A., Salmon, D.P., Merdes, A.,
Gamst, A., Masliah, E., Alford, M., Thal, L.J., Corey-Bloom, J., 2004.
Alzheimer disease without neocortical neurofibrillary tangles: “a sec-
ond look”. Neurology 62, 1141–1147.
omiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi,
K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., Nishitsuji,
K., Ito, K., Shimada, H., Lambert, M.P., Klein, W.L., Mori, H., 2010.
A mouse model of amyloid {beta} oligomers: their contribution to
synaptic alteration, abnormal tau phosphorylation, glial activation, and
neuronal loss in vivo. J. Neurosci. 30, 4845–4856.
an Broeck, B., Vanhoutte, G., Pirici, D., Van Dam, D., Wils, H., Cuijt, I.,
Vennekens, K., Zabielski, M., Michalik, A., Theuns, J., De Deyn, P.P.,
Van der Linden, A., Van Broeckhoven, C., Kumar-Singh, S., 2008.
Intraneuronal amyloid beta and reduced brain volume in a novel APP
T714I mouse model for Alzheimer’s disease. Neurobiol. Aging 29,
241–252.
est, M.J., 2002. Design-based stereological methods for counting neu-
rons. Prog. Brain Res. 135, 43–51.
est, M.J., Slomianka, L., Gundersen, H.J., 1991. Unbiased stereological
estimation of the total number of neurons in the subdivisions of the rat
hippocampus using the optical fractionator. Anat. Rec. 231, 482–497.
irths, O., Bayer, T.A., 2008. Motor impairment in Alzheimer’s disease
and transgenic Alzheimer’s disease mouse models. Genes Brain Behav.
7 suppl 1, 1–5.
irths, O., Bethge, T., Marcello, A., Harmeier, A., Jawhar, S., Lucassen,
P.J., Multhaup, G., Brody, D.L., Esparza, T., Ingelsson, M., Kalimo,
H., Lannfelt, L., Bayer, T.A., 2010. Pyroglutamate Abeta pathology in
APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases.
J. Neural Transm. 117, 85–96.
irths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.U., Bayer,
T.A., 2009. Intraneuronal pyroglutamate-Abeta 3–42 triggers neurode-
generation and lethal neurological deficits in a transgenic mouse model.
Acta Neuropathol. 118, 487–496.
irths, O., Breyhan, H., Schafer, S., Roth, C., Bayer, T.A., 2008. Deficits
in working memory and motor performance in the APP/PS1ki mouse
model for Alzheimer’s disease. Neurobiol. Aging 29, 891–901.
irths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp,
G., Pradier, L., Beyreuther, K., Bayer, T.A., 2001. Intraneuronal Abeta
accumulation precedes plaque formation in beta-amyloid precursor
protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 306,
116–120.
irths, O., Multhaup, G., Czech, C., Feldmann, N., Blanchard, V., Tremp,
G., Beyreuther, K., Pradier, L., Bayer, T.A., 2002. Intraneuronal
APP/A beta trafficking and plaque formation in beta-amyloid precursor
protein and presenilin-1 transgenic mice. Brain Pathol. 12, 275–286.
irths, O., Weis, J., Kayed, R., Saido, T.C., Bayer, T.A., 2007. Age-
dependent axonal degeneration in an Alzheimer mouse model. Neuro-
biol. Aging 28, 1689–1699.
irths, O., Weis, J., Szczygielski, J., Multhaup, G., Bayer, T.A., 2006.
Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer’s
disease. Acta Neuropathol. 111, 312–319.
hu, X., Moreira, P.I., Smith, M.A., Perry, G., 2005. Alzheimer’s disease:
an intracellular movement disorder? Trends Mol. Med. 11, 391–393.
3. Project II: “Evaluating the role of glutaminyl cyclase and 
pyroglutamate-modified Aβ in AD via the 5XFAD/hQC and 5XFAD/QC-
KO mouse models”  
3.1 Overview 
  AβpE3-x represents a major Aβ fraction present in AD patients that is receiving a 
considerable attention due to its higher aggregation propensity, stability and increased toxicity 
compared with full-length Aβ (Gunn et al., 2010). It has been demonstrated that QC is 
involved in the formation of AβpE3-x (Schilling et al., 2004; Cynis et al., 2006; Cynis et al., 
2008a; Gunn et al., 2010).  
Increased QC RNA and protein expression was identified in the cortex of AD patients 
in comparison to non-demented aged controls. This increase in QC was claimed to parallel 
higher AβpE3-42 levels in AD. Oral administration of a QC inhibitor to Tg2576 and TASD-41 
mice reduced AβpE3-x, Aβx-40 and Aβx-42 levels. This reduction was accompanied by a decrease 
in plaque density and gliosis in addition to improvements in contextual fear memory and 
spatial memory (Schilling et al., 2008c). However, both models harbor low AβpE3-x levels and 
milder AD pathology in comparison to the 5XFAD model (Hsiao et al., 1996; Rockenstein et 
al., 2001). 
In order to study the effect of ectopic QC overexpression on overall AD pathology, 
5XFAD mice were crossed with transgenic mice expressing human QC (hQC) under the 
control of the neuron-specific Thy-1 promoter. hQC mice have no obvious phenotype, normal 
life span and breeding performance indicating no severe side effects of the transgene 
integration. 
Moreover, the effect of endogenous QC was studied by generating 5XFAD/QC-KO 
mice (homozygous QC knock-out). The consequences of genetic QC ablation, on endocrine 
function and behavior have been very recently described. Total QC ablation did not show 
effects on fertility, weight or behavior as QC-KO mice performed indistinguishably from wild 
type mice in motor tasks, fear conditioning task, general activity and ingestion behavior 
(Schilling et al., 2011). 
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  The changes in QC levels in the different genotypes were verified at tissue and RNA 
levels. The effect of QC on Aβ and plaque pathology was investigated. Besides, behavioral 
comparison of all the genotypes at different behavioral entities was conducted at 6 months of 
age.  
 
Aims of project II 
- To elucidate in vivo the role played by QC in AD using an aggressive AD mouse 
model. 
- To understand the effect of ectopic QC overexpression on AβpE3-x level in the 5XFAD 
mouse model. 
- To unravel the effects of AβpE3-x increase on the severity of the AD behavioral 
phenotype in the 5XFAD mice. 
- To evaluate the impact of abolishing endogenous QC on AβpE3-x level in the 5XFAD 
mouse model. 
- To determine whether QC-KO can reduce the plaque pathology and rescue the 
behavioral deficits seen in the 5XFAD mouse model.  
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Behavioral Deficits, and Glutaminyl Cyclase Knock-out
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Pyroglutamate-modified A (ApE3–42) peptides are gain-
ing considerable attention as potential key players in the pa-
thology of Alzheimer disease (AD) due to their abundance in
AD brain, high aggregation propensity, stability, and cellular
toxicity. Overexpressing ApE3–42 induced a severe neuron
loss and neurological phenotype in TBA2 mice. In vitro and in
vivo experiments have recently proven that the enzyme glu-
taminyl cyclase (QC) catalyzes the formation of ApE3–42.
The aim of the present work was to analyze the role of QC in
an ADmouse model with abundant ApE3–42 formation.
5XFADmice were crossed with transgenic mice expressing
human QC (hQC) under the control of the Thy1 promoter.
5XFAD/hQC bigenic mice showed significant elevation in
TBS, SDS, and formic acid-soluble ApE3–42 peptides and
aggregation in plaques. In 6-month-old 5XFAD/hQCmice, a
significant motor and working memory impairment developed
compared with 5XFAD. The contribution of endogenous QC
was studied by generating 5XFAD/QC-KOmice (mouse QC
knock-out). 5XFAD/QC-KOmice showed a significant rescue
of the wild-type mice behavioral phenotype, demonstrating
the important contribution of endogenous mouse QC and
transgenic overexpressed QC. These data clearly demonstrate
that QC is crucial for modulating ApE3–42 levels in vivo and
prove on a genetic base the concept that reduction of QC ac-
tivity is a promising new therapeutic approach for AD.
Alzheimer disease (AD)4 is a progressive neurodegenerative
disorder characterized by the presence of extracellular amy-
loid plaques composed of amyloid- (A) and intracellular
neurofibrillary tangles. The discovery that certain early onset
familial forms of AD may be caused by enhanced levels of A
peptides has led to the hypothesis that amyloidogenic A is
intimately involved in the pathogenic process (1).
Besides full-length A 40 and 42 isoforms starting with an
aspartate at position 1, a variety of different N-truncated A
peptides have been identified in AD brains. Ragged peptides
including phenylalanine at position 4 of A have been re-
ported as early as 1985 by Masters et al. (2). In contrast, no
N-terminal sequence could be obtained from cores purified in
a SDS-containing buffer, which led to the assumption that the
N terminus could be blocked (3, 4).
The presence of ApE3 (N-terminally truncated A start-
ing with pyroglutamate) in AD brain was subsequently shown
using mass spectrometry of purified A peptides, explaining
at least partially initial difficulties in sequencing A peptides
purified from human brain tissue (5). The authors reported
that only 10–15% of the total A isolated by this method be-
gins at position 3 with ApE3. Saido et al. (6) and others (7)
subsequently showed that ApE3 represents a dominant frac-
tion of A peptides in AD brain.
Overexpression of ApE3–42 in neurons of TBA2 trans-
genic mice triggers neuron loss and an associated neurological
phenotype (8). N-terminal pE formation can be catalyzed by
glutaminyl cyclase (QC) and is pharmacologically inhibited by
QC inhibitors, both in vitro (9) and in vivo (10). Moreover,
QC expression was found up-regulated in the cortex of pa-
tients with AD and correlated with the appearance of pE-
modified A. Oral application of a QC inhibitor resulted in
reduced ApE3–42 burden in two different transgenic mouse
models of AD as well as in a transgenic Drosophilamodel.
Interestingly, treatment of these mice was accompanied by
reductions in Ax-40/42, diminished plaque formation and
gliosis, as well as improved performance in context memory
and spatial learning tests (10). Thus, ApE3–42 reduction is a
promising target for therapy of AD. In the current work, the
contribution of QC was studied for the first time using ge-
netic means by human QC overexpression and endogenous
QC-knock-out in an AD mouse model.
EXPERIMENTAL PROCEDURES
Transgenic and Knock-out Mice—5XFAD (11) mice have
been described previously. All mice were backcrossed for
* This work was supported by the German Federal Department of Educa-
tion, Science and Technology, Grant 3013185 to a collaborative consor-
tium led by H.-U. D.’s group, including T. A. B.’s team.
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more than 10 generations on a C57BL/6J genetic background
and housed at a 12-h day/12-h night cycle with free access to
food and water. For generation of hQC transgenic mice, an
expression vector containing the cDNA of human QC under
control of the murine Thy1 promoter sequence was con-
structed, applying standard molecular biology techniques and
verified by sequencing. The transgenic founder was generated
on C57BL/6J/CBA background by pronuclear injection (JSW,
Graz, Austria). The resulting offspring were further character-
ized for transgene integration by PCR analysis and after cross-
ing to C57BL/6J wild-type mice for transgene expression by
RT-PCR (more than 10 generations). QC knock-out mice
(QC-KO) were generated on the basis of a classical homolo-
gous recombination approach at Genoway, Lyon. The target-
ing vector contained the mouse chromosomal QC region
ranging from intron 3 to exon 6. This region was modified by
insertion of two LoxP sites in intron 3 and 5, respectively. In
addition, a neomycin resistance cassette flanked by two flip-
pase recognition targets was inserted immediately upstream
of the LoxP in intron 5. After homologous recombination and
chimera production, the neomycin selection cassette was re-
moved by breeding with Flp-expressing mice followed by
breeding of the pups with Cre-expressing mice for deletion of
QC exons 4 and 5. The deletion of exons 4 and 5 causes a
frameshift in the QC open reading frame generating a stop
codon in exon 6. Successful manipulation was confirmed by
PCR and Southern hybridization. Absence of murine QC in
5XFAD/QC-KO comparison with 5XFAD and 5XFAD/hQC
was further confirmed by RT-PCR (supplemental Methods
and supplemental Fig. 1). Animals were handled according to
German guidelines for animal care and studies were approved
by the local legal authorities (LAVES). Only female mice were
used.
Immunohistochemistry—Mouse tissue was processed as
described previously (12). In brief, 4-m paraffin sections
were pretreated with 0.3% H2O2 in PBS to block endogenous
peroxidases, and antigen retrieval was achieved by boiling
sections in 0.01 M citrate buffer, pH 6.0, followed by a 3-min
incubation in 88% formic acid. Primary antibodies were incu-
bated overnight, followed by incubation with biotinylated sec-
ondary antibodies (DAKO) before staining was visualized
using the ABC method with Vectastain kit (Vector Labora-
tories) and diaminobenzidine as chromogen. Alternatively,
fluorochromated secondary antibodies (anti-mouse Alexa
Fluor 594 and anti-rabbit Alexa Fluor 488; Invitrogen) were
used for immunofluorescence detection.
Antibodies—A antibodies NT78 (against generic A; Syn-
aptic Systems), 22C11 (APP; Millipore) and 2–48 (against
N-terminal ApE3; Synaptic Systems) (12) were used. Anti-
sera (against QC) were raised against recombinant full-length
mouse QC (1301) and have been proven to recognize hQC
(13).
ELISA of A Levels in Brain—Frozen brains (n  4–8 per
group) were weighed and subsequently subjected to a sequen-
tial A extraction. In a first step, brains were homogenized in
TBS (120 mM NaCl, 50 mM Tris, pH 8.0, containing complete
protease inhibitor (Roche Applied Science)) using a Dounce
homogenizer, sonified, and subsequently centrifuged at
27,000  g for 20 min at 4 °C. The supernatant was removed
and stored at 80 °C. The pellet was dissolved in 2.5 ml of 2%
SDS, sonificated, and subsequently centrifuged at 80,000  g
for 1 h at 4 °C. Supernatants were directly frozen at 80 °C.
The resulting pellets were again resuspended in 0.5 ml of 70%
formic acid, sonified, and neutralized using 1 M Tris. Aliquots
of the neutralized formic acid fraction were directly frozen at
80 °C. SDS lysates were diluted at least 10-fold for determi-
nation of Ax-42 and ApE3 using ELISA. All dilutions were
carried out using EIA buffer (IBL Co.). The neutralized formic
acid fraction and the TBS fraction were applied directly or
after dilution using EIA buffer. ELISA measurements were
performed in triplicate and according to the protocol of the
manufacturer (IBL Co.; catalog nos. JP27716 and JP27711).
Samples were run in triplicate.
Quantification of Plaque Load—Extracellular A load was
evaluated in mouse brain using an Olympus BX-51 micro-
scope equipped with an Olympus DP-50 camera and the
ImageJ software (V1.41; National Institutes of Health). Serial
images of 40 magnification (hippocampus) and 100 (cor-
tex) were captured on six sections/animal (n  5/group),
which were at least 30 m afar from each other. Using ImageJ
the pictures were binarized to 16-bit black and white images,
and a fixed intensity threshold was applied defining the DAB
staining.
Behavioral Testing—Spontaneous alternation rates were
assessed using Y- and cross-maze as described previously (11,
14). The alternation percentage was calculated as the percent-
age of actual alternations to the total number of arm entries.
Balance and general motor function were assessed using the
balance beam task. A 1-cm dowel beam is attached to two
support columns 44 cm above a padded surface. At either end
of the 50-cm long beam, a 9  15-cm escape platform is at-
tached. The animal is placed on the center of the beam and
released. Each animal is given three trials during a single day
of testing. The time the animal remained on the beam is re-
corded and the resulting latencies to fall of all three trials are
averaged. If an animal remains on the beam for whole 60-s
trial or escapes to one of the platforms, the maximum time of
60 s is recorded (14). For the string suspension test the ani-
mals are permitted to grasp the string by their forepaws and
are released. A rating system from 0 to 5 is used during the
single 60-s trial to assess each animal’s performance in this
task: 0  unable to remain on the string; 1  hangs only by
fore- or hindpaws; 2  as for 1, but attempts to climb onto
string; 3  sits on string and is able to hold balance; 4  four
paws and tail around string with lateral movement; 5  es-
cape. The following numbers of animals were analyzed in this
task (14). The following number of female mice was used at
the age of 6 months: 5XFAD, 11; 5XFAD/hQC, 8; hQC, 11;
5XFAD/QC-KO, 4; QC-KO, 6; wild type, 12.
Statistical Analysis—Statistical differences were evaluated
using one-way ANOVA followed by Bonferroni post hoc test
or unpaired t test as indicated. All data are given as means 
S.E. All statistics were calculated using GraphPad Prism ver-
sion 5.00 software.
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Expression and Distribution of hQC in the Brain of hQC
and 5XFAD/hQC Mice—To study human QC overexpres-
sion in hQC transgenic mice (hQC and 5XFAD/hQC), the
rabbit polyclonal antiserum 1301 recognizing human QC
was used to detect the transgene hQC expression in differ-
ent brain regions (Fig. 1). Because the expression of the
hQC trangene is driven by the Thy1 promoter, abundant
pyramidal neurons expressing hQC were detected in vari-
ous brain regions of hQC and 5XFAD/hQC mice including
the cortex (Fig. 1, A–D), the hippocampus (Fig. 1, E and F),
the midbrain and the cerebellum (data not shown). Nota-
bly, a massive staining of hQC was observed in plaque-as-
sociated dystrophic neurites in 5XFAD/hQC mice (Fig.
1D). Abundant hQC immunoreactivity was detected in
mossy fibers of hQC and 5XFAD/hQC transgenic mice
(Fig. 1, E and F).
Co-localization of APP and QC in Neurons and the Neuritic
Component of Plaques—Double immunofluorescence demon-
strated co-localization of hQC and APP in the same cellular
compartments in the brain of 5XFAD/hQC mice (Fig. 2). APP
markedly labels dystrophic neurites around plaques and
shows abundant co-localization with hQC suggesting that
hQC is axonally transported like APP (Fig. 2).
Effect of hQC Overexpression and QC Knock-out on Plaque
Load in the Frontal Cortex of 6-Month-old 5XFADMice—The
plaque load for total A (NT78) was significantly higher in
5XFAD/hQC compared with 5XFAD mice (5XFAD/hQC,
7.99  1.1%; and 5XFAD, 4.27  0.79%). In 5XFAD/QC-KO
mice, the levels were significantly reduced (1.88  0.43%).
The plaque load for ApE3 showed the same effect. 5XFAD/
hQC (3.08  0.44%) had significantly elevated levels com-
pared with 5XFAD mice (1.83  0.31%) and reduced in
5XFAD/QC-KO mice (0.55  0.12%) (Fig. 3).
FIGURE 1. Immunohistochemical staining of hQC in hQC and 5XFAD/hQC mice. Expression of human transgenic QC was detected in pyramidal neurons
in the cortex of hQC (A and C) and 5XFAD/hQC mice and in plaque-associated dystrophic neurites (arrows) of 5XFAD/hQC mice (B and D). In addition, hQC
staining was detected in mossy fibers of the hippocampal formation of hQC and 5XFAD/hQC mice (E and F). Scale bars, 100 m (A and B), 50 m (C and D),
200 m (E and F).
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Effect of hQC Overexpression and QC Knock-out on Ax-42
and ApE3–42 Levels of 6-Month-old 5XFADMice—Protein
quantification of Ax-42 (in micrograms/gram of brain
weight) and ApE3–42 (in nanograms/gram of brain weight)
levels in brain lysates of 6-month-old 5XFAD, 5XFAD/hQC,
and 5XFAD/QC-KO mice revealed significant differences
(Fig. 4). In the SDSFA-soluble fraction there was a signifi-
cant 48% reduction (p  0.01) of Ax-42 levels in 5XFAD/
QC-KO mice (41.07  4.79) compared with 5XFAD (78.52 
6.54). There was, however, no difference of Ax-42 levels in
the TBS-soluble fraction in 5XFAD/hQC (0.09  0.02) com-
pared with 5XFAD (0.12  0.01) and 5XFAD/QC-KO mice
(0.09  0.01). The effects were more pronounced on
ApE3–42 levels. There was an 86% elevation (p  0.01) of
ApE3–42 levels in the TBS-soluble fraction in 5XFAD/hQC
(0.12  0.02) compared with 5XFAD (0.07  0.01) and unde-
tectable levels in 5XFAD/QC-KO mice. In the SDSFA frac-
tion an 84% elevation (p  0.001) of ApE3–42 levels was
found in 5XFAD/hQC (114.9  5.89) compared with 5XFAD
(62.29  3.66) and significantly reduced levels (38%) in
5XFAD/QC-KO mice (38.59  1.93, p  0.01, compared with
5XFAD) (Fig. 4). Despite the differing Ax-42 and ApE3–42
levels in 5XFAD, 5XFAD/hQC, and 5XFAD/QC-KO mice,
expression levels of transgenic human APP and PS1 were un-
changed (supplemental Fig. 2).
Effect of hQC Overexpression and QC Knock-out on Behav-
ioral Performance in 5XFADMice—Motor coordination was
assessed by using balance beam and string suspension tasks
(Fig. 5, A and B). In both tasks the 5XFAD/hQC performed
significantly worse that 5XFAD (p  0.001 and p  0.01, re-
spectively). Working memory was assessed using Y- and
cross-maze alternation tasks. Analysis in the Y-maze revealed
FIGURE 2. Transgene human QC is co-localized with APP. Double immunostaining in the cortex of 5XFAD/hQC mice using antibodies against APP (red; A
and E), QC (green; B and F) and DAPI (blue; C and G). APP and QC showed co-localization in dystrophic neurites of plaques and in the somatodendritic com-
partment of pyramidal neurons in the merged images (yellow; D, H, inset in H). Scale bars, 50 m (A–D), 20 m (E–H).
FIGURE 3. Effect of hQC overexpression and QC knock-out on plaque load in 5XFAD mice. A, plaque staining in the cortex using antibodies against ge-
neric A (NT78) and pyroglutamate-modified A (2– 48) in 5XFAD, 5XFAD/hQC, and 5XFAD/QC-KO mice. B, quantification of plaque load demonstrating
significantly elevated A and ApE3 levels in 5XFAD/hQC and significantly reduced levels in 5XFAD/QC-KO mouse brain. Scale bar, 200 m. *, p  0.05; **,
p  0.01. Error bars, S.E.
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a significantly reduced alternation frequency in 5XFAD/hQC
compared with 5XFAD mice (p  0.05). The number of arm
entries during the test period was not different between the
groups (Fig. 5, C and D). Assessment using the more complex
cross-maze task demonstrated again a significantly reduced
alternation frequency in 5XFAD/hQC compared with 5XFAD
mice (p  0.05), and 5XFAD versus wild-type mice (p  0.05).
The latter finding corroborated previous results (14). More-
over, the working memory deficit of 5XFAD mice was rescued
in 5XFAD/QC-KO mice (p  0.05) showing alternation fre-
quencies indistinguishable from wild-type mice. The number
of arm entries during the test period was not different among
all groups (Fig. 5, E and F).
DISCUSSION
Schilling et al. have shown that cyclization of glutamate at
position 3 of A can be driven enzymatically by QC in vitro
(15). In addition, it has been demonstrated that QC inhibition
significantly reduced ApE3 formation in vivo, emphasizing
the importance of QC activity during cellular maturation of
pyroglutamate-containing peptides. The pharmacological
inhibition of QC activity by the QC inhibitor PQ150, which
significantly reduced the level of ApE3 in vitro (16) and in
vivo (10), suggests that QC inhibition might serve as a new
therapeutic approach. Furthermore, the mean level of ApE3-
IgM autoantibodies was significantly decreased in AD pa-
tients compared with healthy controls. In the group of mildly
cognitive-impaired patients there was a significant positive
correlation between ApE3-IgM and cognitive decline (17).
Interestingly, APP/PS1KI mice, a model with severe neuron
loss in the hippocampus, accumulate a large heterogeneity of
N-truncated Ax-42 isoforms including ApE3 peptides co-
inciding with the onset of behavioral deficits (18, 19). More
specifically, transgenic mice expressing only ApE3–42 de-
veloped a robust and lethal neurological phenotype accompa-
nied by Purkinje cell loss (TBA2 mouse line) (8).
Saido et al. suggested that hypothetically the removal of
N-terminal amino acids 1 and 2 of A might be carried out by
amino or dipeptidyl peptidase(s) (6). Aminopeptidase A may
be responsible in part for the N-terminal truncation of full-
length A peptides (20).
N-truncated ApE3 peptides have been identified by sev-
eral groups in AD brains (5, 6, 21–32). N-terminal deletions in
general enhance aggregation of -amyloid peptides in vitro
(33). ApE3 has a higher aggregation propensity (34, 35) and
stability (36) and shows an increased toxicity compared with
full-length A (37). It has been also suggested that N-trun-
cated A peptides are formed directly by -secretase and not
through a progressive proteolysis of full-length A1–40/42
(38).
APP transgenic mouse models have been reported to show
no (23) or low ApE3 levels (31). Maeda et al. have demon-
strated that the localization and abundance of [11C]Pittsburgh
compound B autoradiographic signals were closely associated
with those of N-terminally truncated and modified ApE3
deposition in AD and different APP transgenic mouse brains,
implying that the detectability of amyloid by [11C]Pittsburgh
compound B-positron emission tomography is dependent on
the accumulation of specific A subtypes (39). APP/PS1KI
(12, 18) and 5XFAD (14) mice harbor abundant A3pE levels.
Interestingly, both models develop an age-dependent neuron
loss and robust behavioral deficits, like TBA2 mice with only
ApE3–42 expression (8).
The findings of the present work are in good agreement
with the previous observations that ApE3–42 levels corre-
late with behavioral deficits in transgenic mouse models.
Here, we demonstrate for the first time genetic evidence for
QC as a major target for AD. Overexpression of human QC is
co-localized with APP in the neuritic component of plaques,
leading to elevated ApE3–42 levels as detected by ELISA.
This finding is corroborated by an increase in the overall
plaque pathology including ApE3–42 in 5XFAD/hQC mice.
Consistently, 5XFAD/hQC mice developed a neurological
phenotype demonstrated by learning and memory impair-
ments compared with the 5XFAD mouse model at 6 months
FIGURE 4. Effect of hQC overexpression and QC knock-out on A levels
in 5XFAD mice. Quantification of Ax-42 and ApE3– 42 using ELISA
showed significant changes in TBS, SDS, and formic acid (FA) fractions in
5XFAD, 5XFAD/hQC, and 5XFAD/QC-KO mouse brain. SDS and FA fractions
were pooled for quantification. Ax-42 levels were significantly reduced in
the SDSFA fraction of 5XFAD/QC-KO mice. ApE3– 42 levels were signifi-
cantly elevated in all fractions in 5XFAD/hQC mice. Although in the TBS
fraction of 5XFAD/QC-KO mice the levels of ApE3– 42 were below the limit
of quantitation, in the SDSFA fractions of 5XFAD/QC-KO mice the levels of
ApE3– 42 were significantly reduced. **, p  0.01; ***, p  0.001. LOQ, limit
of quantitation. Error bars, S.E.
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of age. In addition, we could also show that knock-out of en-
dogenous QC is sufficient to lower A levels, including
ApE3–42, leading to a concomitant rescue of behavioral
deficits in 5XFAD mice. The apparent discrepancies between
Ax-42 and ApE3–42 are likely because the Ax-42 pep-
tides are 1000 times more abundant than ApE3–42 (mi-
crograms versus nanograms/g wet weight). Therefore it is un-
likely that an hQC-dependent increase in ApE3–42 levels is
reflected in a concomitant increase of Ax-42 levels in a stoi-
chiometric manner. It is, however, surprising that the level of
Ax-42 is significantly reduced in 5XFAD/QC-KO mice. This
might be due to a reduced seeding effect of ApE3–42 on
full-length A, which is therapeutically of interest. It is hy-
pothesized that ApE3–42 elevation does not necessarily lead
to increased aggregation of Ax-42, which might be due to a
saturation effect. In addition, the differences in the plaque
load of total A and Ax-42 levels measured by ELISA might
be because plaque load was done in the cortex whereas ELISA
was performed in whole brain lysates.
Because ApE3–42 levels were not completely reduced, we
assume that other QC-related enzymes like isoQC are respon-
sible for the residual formation of pyroglutamate in QC-KO
FIGURE 5. Effect of hQC overexpression and QC knock-out on behavioral performance in 5XFAD mice. A and B, 5XFAD/hQC mice showed a signifi-
cantly reduced motor performance in balance beam (A) and string suspension task (B) compared with 5XFAD mice. C, in addition, working memory deficits
were detected in 5XFAD/hQC compared with 5XFAD mice using Y- and cross-maze (E). Interestingly, the 5XFAD/QC-KO mice showed a rescue of working
memory deficits with alternation frequencies indistinguishable from wild-type mice. D and F, the number of arm entries in Y- and cross-maze did not differ
among the groups. *, p  0.05; **, p  0.01; ***, p  0.001.
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mice. QC and isoQC represent very similar proteins, which
are both present in the secretory pathway of cells. The func-
tions of QCs and isoQC complement each other, suggesting a
pivotal role of pyroglutamate modification for protein and
peptide maturation (40). To analyze a possible contribution of
isoQC to the remaining QC-like activity in 5XFAD/QC-KO
mice, we performed a Western blot analysis using an isoQC
antibody. The protein levels of isoQC were unchanged in dif-
ferent brain regions between WT and QC-KO mice. This ob-
servation demonstrates that the finding of residual pyrogluta-
mate A levels in 5XFAD/QC-KO mice is likely mediated by
isoQC (supplemental Fig. 3). In conclusion, reduction of QC
was sufficient to rescue the behavioral impairments in the
5XFAD mouse model suggesting a crucial role of QC as a
therapeutic target for AD.
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Supplementary Information Jawhar et al. 
 
Real time-PCR 
For real-time RT-PCR analysis six-month-old female mice were used (5XFAD, 5XFAD/hQC, 
5XFAD/QC-ko). Mice were killed by CO2 asphyxiation, brain hemispheres were carefully 
dissected, snap frozen in liquid nitrogen and stored at –80 °C until further analysis. Deep 
frozen brain hemispheres were homogenized in 1 ml of Trizol reagent (Invitrogen) per 
100 mg tissue using a glass-teflon homogenizer (10 strokes, 800 rpm). RNA extraction was 
performed according to the protocol of the manufacturer. DNAse treatment and Reverse 
transcription of RNA of the purified RNA samples was carried out using QuantiTect Reverse 
Transcription Kit (Qiagen, Hilden, Germany) according to the protocol of the supplier. RT-
PCR was performed using a Stratagene MX3000P Real-Time Cycler. The SYBR-green based 
DyNAmo Flash SYBR Green qPCR Kit (Finnzymes) containing ROX as an internal reference 
dye was used for amplification. Primer sets detecting murine QC (mQC) and β-Actin were 
purchased from Qiagen (QuantiTect Primer Assays: murine QC: Mm_Qpct_3_SG (Amplicon 
length: 117 bp); murine β-Actin: Actb_1_SG (Amplicon length: 149 bp, Qiagen, Hilden, 
Germany). The resulting PCR products from the RT-PCR were in addition run on a 2.5% 
agarose gel.  
 
Western Blot 
20µg of the brain lysates per lane was loaded on 4-12% sodium dodecylsulfate 
polyacrylamide gels (Vario-Gel, Anamed, Germany) and run at 150 V for 1 hour. Proteins 
were transferred to a nitrocellulose membrane for 2 hours at 25 V using wet transfer. After 
transfer, membrane was blocked in 10% non-fat dry milk in TBS containing 0.05% Tween 
(TBS-T) for 1 hour. The membrane was then incubated overnight using mouse monoclonal 
antibody W0-2 (1:5000, Millipore) to detect APP, polyconal antiserum 3109 against PS1 
(1:1000, generous gift from Prof. Jochen Walter, Bonn), polyclonal antiserum 5407 against 
isoQC (1:1000, Probiodrug) and mouse monoclonal antibody detecting β-Actin (β-Actin, 
1:5000, Sigma). The bound antibodies were detected by secondary HRP-conjugated 


















































Supplementary Figure 1: Absence of mQC in the 5XFAD/QC-ko mice. (A) RT PCR was 
used to compare the expression level of murine QC in 5XFAD, 5XFAD/hQC and 
5XFAD/QC-ko. No mQC expression could be detected in 5XFAD/QC-ko mice. The very late 
rise in fluorescence is due to the formation of a primer dimer in the absence of the target 
sequence. This has been verified by melting curve analysis (not shown), as well as by agarose 
gel electrophoresis (B). RT PCR for the β-Actin was used as a control for the amount and 































































Supplementary Figure 2: QC overexpression and QC knockout did not affect amyloid 
precursor protein (APP) or presenilin 1 (PS1) levels in 5XFAD mice. Western blot using 
W0-2 detecting APP and antiserum 3109 detecting PS1 revealed no difference in the 
expression levels of both proteins among 5XFAD, 5XFAD/hQC and 5XFAD/QC-ko mice. β-





Supplementary Figure 3: Unchanged expression levels of isoQC in WT and QC–ko 
mice. Western blot analysis of isoQC in different brain regions in WT and QC–ko mice. 












































4.1 Project I: “Characterization of the 5XFAD mouse model” 
Over the past years, many mouse models have been generated based on FAD 
mutations to mimic AD pathology. These models contributed widely to our understanding of 
the changes occurring on molecular, tissue and clinical levels. Moreover, they represent 
essential tools for preclinical testing of therapeutic approaches. However, most of these 
models are limited either by harboring mild or late pathology or lacking some of the cardinal 
AD hallmarks. The introduction of multiple FAD mutations in APP and PS1 in transgenic 
mice aimed at accelerating and increasing the AD pathology to resemble that found in AD 
patients. 
The 5XFAD mouse model is a double transgenic APP/PS1 mouse model that 
expresses five FAD mutations leading to a higher Aβx-42 level and accelerated amyloid 
deposition (Oakley et al., 2006). The co-expression of five FAD mutations results in early 
multiple AD pathological hallmarks. As this model lacks NFTs formation, it represents an 
amyloid-predominant model of AD. The 5XFAD mouse model shares this accelerated 
aggressive AD pathology with other APP/PS1 AD models such as APP/PS1KI (Casas et al., 
2004) and APP/PS1 (Schmitz et al., 2004). However, the 5XFAD mice are particularly 
interesting due to the co-integration of the APP and PS1 transgenes at the same genetic locus 
and thus the co-segregation of the transgenes. This facilitates breeding and genotyping and 
more importantly enables easy generation of bigenic mouse models.  
The 5XFAD mice were originally generated and described on a B6/SJL-hybrid 
background. They were reported to develop early plaque deposition associated with gliosis in 
addition to neuron and synaptic loss and memory deficits (Oakley et al., 2006). The objectives 
of the present study were to validate and extend the findings in the 5XFAD mouse model after 
being backcrossed with C57BL/6J mice, to facilitate the comparison with other models which 
are mostly kept on the C57BL/6J genetic background. This is particularly important because 
the genetic background has been reported to have potential influence on the APP processing, 
the behavioral performance, the neuropathology and the response to excitotoxicity (Carlson et 
al., 1997; Lehman et al., 2003; Lassalle et al., 2008; Glazner et al., 2010). 
61
4.1.1 The 5XFAD mouse model shows age-dependent neurological deficits and motor 
impairments 
AD is characterized by progressive cognitive impairments in addition to 
neuropsychiatric symptoms such as anomalous motor behavior, depression, weight loss, 
irritability and agitation. In the current study, the neurological deficits and the motor 
performance in the 5XFAD mice were investigated.  
The 5XFAD mice exhibited reduced body weight in comparison to their wildtype 
littermates starting from 9 months of age. Weight loss occurs frequently in AD patients 
(Tamura et al., 2007) and in some AD mouse models such as the TASTPM (Pugh et al., 
2007). Moreover, 12-month-old 5XFAD mice showed an abnormal extension reflex by 
retracting hind- and fore-paws simultaneously when suspended by the tail. This abnormal 
reflex has been correlated with pathology in the spinal cord, cerebellum, basal ganglia, 
forebrain, hindbrain and midbrain in other models. It has been described in several AD models 
such as APP23 (Lalonde et al., 2005), Tg2576 (Lalonde et al., 2003b; Seo et al., 2010) and 
APP/PS1KI mouse models (Wirths et al., 2007).  
In line with the clasping behavior, the motor phenotype started to become prominent in 
5XFAD mice at 9 months of age. This was indicated using the balance beam, which reflects 
balance and general motor abilities (Arendash et al., 2001a) and the string suspension task, 
which reflects agility and grip capacity (Moran et al., 1995). Impairments in motor 
coordination might be due to pathology in different CNS regions such as the cerebellum, the 
basal ganglia, the neocortex and the spinal cord (Lalonde and Strazielle, 2007; Wirths and 
Bayer, 2008). However, due to the use of the Thy-1 promoter construct, the transgene 
expression in the cerebellum is restricted. Therefore, axonal deficits, loss of connecting 
neurons with the cerebellum and/or impairment of other brain regions, like the motor cortex 
and the basal ganglia, might account for the described motor phenotype. Motor deficits in 
these tasks or other motor tasks have been detected in some AD mouse model such as APP 
single transgenic mice like Tg2576 (Arendash et al., 2001b), APP23 (Van Dam et al., 2003) 
and Tg-APP mice (Sw, V717F) (Lee et al., 2004) and double transgenic APP/PS1 mice such 
as APP+PS1 (Ewers et al., 2006). The assessment of motor impairment is a highly relevant 
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issue, as some reference memory tasks like the Morris water maze are severely influenced by 
any disturbance in motor performance, leading to erroneous results. 
Motor impairments are widely described in AD patients and are already present at 
early stages of the disease in 13% of the patients at the first examination, progressing to 36% 
at the last examination. These signs included poverty in speech/facial expression, rigidity, 
posture/gait disturbances and bradykinesia (Scarmeas et al., 2004). Gait disturbance was 
reported in 40% of AD patients in comparison to 18% of age-matched control patients 
(O'Keeffe et al., 1996). Prospective studies suggested the motor impairments to have a 
predictive value for the cognitive decline in AD and to be useful in identifying MCI patients at 
risk of developing AD (Chui et al., 1994; Aggarwal et al., 2006). 
Taken together, the 5XFAD mice show age-dependent neurological and motor deficits 
which mimic common phenotypes seen in AD patients and found in some AD mouse models. 
 
4.1.2 The 5XFAD mouse model shows early pathological deficits in the spinal cord 
Impairments in axonal transport have been described in AD patients (Stokin et al., 
2005) and many AD and DS mouse models to variable extents (Stokin et al., 2005; Salehi et 
al., 2006; Wirths et al., 2006; Wirths et al., 2007; Coma et al., 2010). As mentioned above, 
motor impairments are quite common at different stages of AD, raising the question whether 
axonal transport deficits might contribute to these impairments.   
To elucidate whether the clasping phenotype and the motor impairments of the 
5XFAD mice coincide with axonal deficits, screening for axonal swellings in the spinal cord 
using a marker for neurofilaments (NF200), which are the most abundant fibrillar component 
of the axons, was performed. Plaque-independent axonal spheroids were quantified in an age-
dependent manner because they may represent disturbance in the axonal transport rather than 
local toxic effects of plaques. However, staining against neurofilaments together with Aβ 
peptides revealed many axonal swellings in the form of small dystrophic neurites decorating 
the neuritic plaques. 
Axonal spheroids were present mainly in the gray matter as early as 3 months of age 
and showed age-dependent increase, a pattern that was also seen in the pons. In line with our 
findings, dystrophic neurites and plaque-independent axonal spheroids have been recently 
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detected in the brain of 5XFAD mice as early as 2 months of age (Zhang et al., 2009). Axonal 
swellings have been previously reported in other AD transgenic mouse models such as 
APP/PS1KI and APP/PS1 to a variable extent (Wirths et al., 2006; Wirths et al., 2007). They 
were also reported in tau-based (Spittaels et al., 1999; Probst et al., 2000) or APOE-based 
models (Tesseur et al., 2000) which also show different forms of motor deficits. In good 
agreement, APP-positive spheroids were demonstrated in the spinal cord of early-onset AD 
patients, a finding that may contribute to the understanding of the motor deficits seen in AD 
(Wirths et al., 2007). 
Previous studies in APP/PS1 mouse models suggested that intraneuronal Aβ 
contributes to the axonal impairments in these mice (Wirths et al., 2006; Wirths et al., 2007; 
Chen et al., 2011). Interestingly, intraneuronal Aβ was detected within the spinal cord motor 
neurons of the 5XFAD mice as early as 3 months of age, which might be involved in the 
axonal transport impairment. This is supported by the finding that Aβx-42 accumulates in 
lumbar motor neurons of patients suffering from amyotrophic lateral sclerosis (ALS) 
(Calingasan et al., 2005), a disease in which axonal transport deficits are clearly implicated 
(Chevalier-Larsen and Holzbaur, 2006).  
Although many studies investigated the tau pathology in the spinal cords of AD 
patients (Saito and Murayama, 2000), few studies analyzed the presence of amyloid pathology 
in this region (Bugiani et al., 1989; Ogomori et al., 1989). Plaque deposits in the spinal cord 
have been recently described in AD mouse models such as Tg2576 (Seo et al., 2010). To 
evaluate the plaque pathology in the spinal cord of the 5XFAD mouse model, plaque load was 
quantified in the gray matter of the spinal cord of 3-, 6- and 12-month-old mice and showed a 
significant increase with age. This pattern has also been reported in other APP/PS1 models 
(Wirths et al., 2006; Wirths et al., 2007). In both models, the presence of plaque pathology in 
the spinal cord was preceded by the presence of intraneuronal Aβ. Although earlier time 
points were not investigated in the current project, work from Zhang et al. (2009) indicated 
that intracellular Aβ and axonal swellings existed as early as 1 month of age and preceded the 
plaque deposition in the brain of 5XFAD mice. Moreover, recent data from an APP/PS1 
model supports the current findings. It was shown that intraneuronal Aβ preceded plaque 
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deposition which correlated well with the axonal alterations in the corpus callosum and the 
anterior commissure of APP/PS1 mice (Chen et al., 2011). 
In summary, the current work sheds light on the neurological symptoms, motor 
impairments, axonopathy and spinal cord pathology in the 5XFAD mouse model which have 
not been assessed before. Accumulation of intraneuronal Aβ coincides with the axonal 
impairments in the spinal cord of 5XFAD mice that are represented by axonal spheroids and 
motor phenotype. Nevertheless, this does not rule out that pathological changes in other 
regions involved in motor activity may also contribute to the neurological and motor 
phenotype seen in the 5XFAD mice. 
 
4.1.3 Neuron loss in 5XFAD mice correlates with the presence of intraneuronal Aβ 
Neuron loss and atrophy are among the major neuropathological hallmarks seen in AD 
patients, and their extent and distribution depends on the severity of the disease. Among the 
various AD mouse models, only a few exhibit neuron loss, and they are mostly those which 
harbor multiple FAD mutations (Wirths and Bayer, 2010). Loss of neurons was previously 
assumed in 9-month-old 5XFAD mice, however, this was not appropriately quantified 
(Oakley et al., 2006; Ohno et al., 2007). For this reason, designed-based stereology was 
utilized to quantify neurons in the CA1 region and the overall frontal cortex of 12-month-old 
5XFAD mice. No significant neuron loss could be detected in these regions. The absence of 
neuron loss in CA1 was supported by a very recent paper by Shao and colleagues who 
reported no neuron loss in the CA1 region of 6-month-old 5XFAD mice (Shao et al., 2011).  
 The fifth cortical layer was specifically studied, which, together with the subiculum, 
was previously assumed to have neuron loss (Oakley et al., 2006). In agreement, 12-month-
old 5XFAD females showed about 40% less neuron in the fifth cortical layer of the frontal 
cortex compared to wildtype littermates. In line with our findings in the fifth cortical layer, a 
very recent paper by Lemmens and colleagues revealed similar findings in APP/PS1KI mice. 
The authors found a 34% neuron loss in V–VI layers of the frontal cortex of 10-month-old 
APP/PS1KI mice compared to 2-month-old mice, while no neuron loss could be detected in 
the I-IV layers of the frontal cortex (Lemmens et al., 2011).  
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The frontal cortex is among the brain regions that are known to be affected in AD 
(Braak et al., 1996) contributing to the memory, behavioral and cognitive symptoms seen in 
AD patients. Pyramidal neurons in the fifth cortical layers are particularly important for 
corticospinal, corticostriatal and corticocortical connections (Bussiere et al., 2003; Anderson 
et al., 2010). These neurons have been reported to be particularly vulnerable in the course of 
AD (Morrison and Hof, 2007). 
Growing evidence compiled during the last years points to the role played by 
intraneuronal Aβ in the neurodegeneration process in AD (Gouras et al., 2010; Bayer and 
Wirths, 2011). In this regard, accumulation of intraneuronal Aβ in the hippocampus and the 
cortex was investigated. The major difference between the fifth cortical layer and the CA1 
was the intraneuronal accumulation of Aβ, although both regions expressed comparable levels 
of the APP immunoreactivity and presented extracellular amyloid deposition. Intraneuronal 
Aβ accumulation was prominent in the pyramidal neurons of the fifth cortical layer in 
comparison to other cortical layers, which is due to the Thy-1 driven transgene expression 
pattern (Feng et al., 2000). This might account for the discrepancy in the neuron loss between 
the overall frontal cortex and the fifth cortical layer. The observations in the 5XFAD mice 
confirm previous findings in APP/PS1KI mice, where neuron loss occurred only in brain 
regions showing intraneuronal Aβ accumulation, like the frontal cortex, CA1 or distinct 
cholinergic brain stem nuclei. In the thalamus or the striatum, regions where only extracellular 
plaques were detectable, no neuron loss could be demonstrated (Casas et al., 2004; Schmitz et 
al., 2004; Christensen et al., 2008; Breyhan et al., 2009) arguing against a significant role of 
extracellular plaques in terms of Aβ toxicity. In addition, data from a new APP transgenic 
mouse model harboring the E693Δ mutation support these observations. This model does not 
show any extracellular amyloid deposits even at 24 months of age. However, it demonstrates 
CA3 neuron loss at this time point which is preceded by intraneuronal Aβ oligomer 
accumulation (Tomiyama et al., 2010). Recently, the use of a novel gene transfer technique 
with a lentiviral Aβ1–42 resulted in intracellular but not extracellular Aβ accumulations in the 
targeted rat primary motor cortex. Expression of intracellular Aβ1–42 led to pathological 
changes seen in human AD brains, including cell death (Rebeck et al., 2010). On the contrary, 
some studies suggest a correlation between neuron loss and extracellular plaque deposition. 
66
Triple immunostaining combined with confocal microscopy showed dramatic focal neuronal 
toxicity associated primarily with fibrillar Aβ deposits in AD and PSAPP mice. These results 
led the authors to suggest that Aβ develops neurotoxic properties in vivo when it adopts a 
fibrillar β-pleated sheet conformation (Urbanc et al., 2002). 
Interestingly, intraneuronal Aβ in the fifth cortical layer showed strong 
immunoreactivity at 3 months of age which decreased with aging until it was almost absent at 
12 months of age. This observation can be due to the neuron death occurring in cells harboring 
Aβ leading to a loss of intraneuronal Aβ signal with age. A similar pattern has been reported 
in the TBA2.1 mouse model were death of the neurons was associated with reduced 
intraneuronal Aβ signal (Alexandru et al., 2011). 
Altogether, findings from the current work confirm and quantify neuron loss described 
previously in the 5XFAD mice on a different genetic background. Also, it strongly suggests 
that neuron loss draws a parallel to the intraneuronal Aβ observed in specific brain regions in 
this mouse model. 
 
4.1.4 Spatial working memory impairment in the 5XFAD mouse model 
AD is an amnesic disorder with multiple forms of memory being affected, including 
the working memory. In rodents, spatial working memory evaluates recent memories related 
to their foraging behavior in the wild (Dember and Fowler, 1958). It has been proven that the 
hippocampus, the prefrontal cortex and the hippocampal-prefrontal cortical circuit are 
important for working memory (Divac, 1975); and these brain areas are among the regions 
known to be affected in AD. Oakley et al. (2006) reported deficits in spatial working memory 
in 4 to 5-month-old 5XFAD mice as reflected by reduced alternation percentage in the Y-
maze. Due to that, spatial working memory was analyzed to test whether the previously 
published impairment in the Y-maze task (Oakley et al., 2006) is still detectable in mice kept 
on the new genetic background. For this purpose, 5XFAD mice were tested in the cross-maze 
test in the first project (Chapter 2). Moreover, 5XFAD mice were compared to wildtype and 
other transgenic littermates in the second project (Chapter 3). In agreement with the previous 
results, the 5XFAD mouse model showed an age-dependent reduction in the spatial alternation 
percentage in the cross-maze starting from 6 months of age. It is noteworthy to mention that 
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this reduction was not due to a decreased motor activity because 5XFAD mice showed 
comparable arm entries to their wildtype littermates. On the other hand, no change in the 
spatial alternation could be detected when 6-month-old 5XFAD mice were tested in the Y-
maze. The only difference between the two tests lies in the higher level of complexity of the 
cross-maze because it has four arms instead of the three arms in the Y-maze. This makes it 
more challenging and thus more sensitive in detecting memory impairments. The different 
genetic backgrounds may underlie the discrepancy in the Y-maze performance between the 
current work and the work of Oakley et al. (2006). Genetic background has been reported to 
influence the performance of inbred wildtype mice (Holmes et al., 2002) and AD mouse 
models (Lassalle et al., 2008; Glazner et al., 2010). These differences in behavior might be 
due to genetic influences on neural development and thus on neuroanatomical, neurochemical, 
cellular, and molecular substrates associated with behavior.  
 Several AD models presented decreased spatial alternation levels with age, such as the 
Tg2576 (Ognibene et al., 2005) and the TASTPM (Howlett et al., 2004) mouse models. Other 
mouse models, such as the C3-3, E1-2 (Savonenko et al., 2003) and the APPswe + 
PS1/DeltaE9 (Lalonde et al., 2004), lacked this deficit. 
 Although no neuron loss could be detected in the hippocampus of the 5XFAD mice 
that may account for their spatial working memory impairment, Kimura and Ohno (2009) 
reported hippocampal CA1 synaptic failures in the form of basal synaptic transmission and 
LTP reduction at 6 months of age but not at 4 months of age. This LTP reduction correlated 
with reduced hippocampus-dependent formation of contextual fear memory. In agreement, the 
level of PSD-95, a major postsynaptic scaffold protein, was markedly decreased in the apical 
dendrites with a prominent immunoreactivity in neuronal soma in CA1 neurons of 6-month-
old 5XFAD mice compared to 3-month-old 5XFAD mice (Shao et al., 2011). These findings 
may in part explain the reduced spatial alternation seen in the 5XFAD mice at 6 months of age 
and not at 3 months of age.  
In summary, the current work recapitulates the spatial working memory impairment 




4.1.5 Reduced anxiety in 5XFAD mice 
In addition to cognitive impairment, a wide range of noncognitive neuropsychiatric 
changes are observed in AD. One of these symptoms is disinhibition, which is present in 25-
30% of patients (Cummings, 2000). Disinhibition is manifested by socially unacceptable 
behavior and inappropriate euphoria (Chung and Cummings, 2000). The elevated plus maze 
measures the anxiety level in the mice. More time spent in the open arms reflects reduced 
anxiety and disinhibition, whereas less time spent in the open arms is an indication of 
increased anxiety levels. AD mouse models showed inconsistent anxiety tendencies. Some 
AD mouse models such Tg2576 (Ognibene et al., 2005), TASTPM (Pugh et al., 2007), PS1-
A246E (Lalonde et al., 2003a) and APP/PS1KI (Faure et al., 2011) mice displayed reduced 
anxiety, whereas other AD mouse models, such as the APP23 model did not demonstrate any 
change in its anxiety levels (Lalonde et al., 2002). On the other hand, other mouse models 
showed increased anxiety as revealed by enhanced innate and conditioned fear symptoms such 
as the 3xTg model. Elevated anxiety was claimed to correlate with the presence of 
intraneuronal Aβ in the amygdala (Espana et al., 2009). When the 5XFAD mice were tested in 
the elevated plus maze, they showed reduced anxiety as reflected by increased time spent in 
the open arms compared to their wildtype littermates. This phenotype was first detected at 6 
months of age. Interestingly, a very recent study showed that treatment of the 5XFAD mice 
with an antibody against low molecular weight AβpE3-x oligomers from 4.5 months to 6 months 
of age stabilized the decline in the anxiety to the point when the treatment started (4.5 months) 
(Wirths et al., 2010b). This finding sheds light on the effect of the low molecular weight 
AβpE3-x oligomers on the disinhibition phenotype seen in 5XFAD mice.  
Analysis of anxiety, exploration and locomotor activity in the open field paradigm 
confirmed the reduction in anxiety detected using elevated plus maze. The 5XFAD mice spent 
more time in the central region of the maze compared with their wildtype littermates. In 
contrast, locomotor behavior did not seem to be affected since there was no difference 
detected in the speed or the traveled distance during the 5 minutes of testing. Changes in the 
locomotor activity in the open field have been reported in some AD mouse models. Certain 
mice exhibited increased locomotor activity, such as TgCRND8 mice (Walker et al., 2011), 
APPC100.V717F transgenic (Boon et al., 2010), Tg2576 (Deacon et al., 2009) and 3xTg 
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(Pietropaolo et al., 2008). Other mouse models presented reduced activity, such as APP751SL 
(Le Cudennec et al., 2008). On the other hand, other models were reported to have no obvious 
phenotype in the open field such as APPswe + PS1/DeltaE9  (Lalonde et al., 2004). 
In conclusion, the current findings demonstrate for the first time changes in the anxiety 
level and the disinhibition phenotype of the 5XFAD mice as detected in the elevated plus 
maze and confirmed using the open field task. 
 
4.1.6 Plaque pathology and pyroglutamate-modified Aβ in 5XFAD mice  
As expected in an APP/PS1 bigenic AD model, the 5XFAD mouse model was 
reported to develop extracellular plaque deposition as early as 2 months of age. The plaques 
first appeared in the deep layers of the cortex, the subiculum and the hippocampus. With age, 
plaques spread to cover most of the brain regions (Oakley et al., 2006). However, age-
associated dynamic changes in plaque pathology were never quantified. Therefore, two pools 
of Aβ plaques, in the hippocampus and the cortex, were analyzed at 3, 6 and 12 months of 
age. These brain regions were chosen because they are the first regions where the plaque 
pathology starts. Also, as indicated above, these regions show differential intraneuronal Aβ 
accumulation and neuron loss despite the presence of plaques. Moreover, they are relevant to 
the pathological and behavioral changes seen in the 5XFAD mice.  
The area covered with Aβ plaques detected with a pan A antibody showed significant 
and continuous increase with age in both the cortex and the hippocampus. In the 5XFAD 
mice, the Swedish mutation produces higher levels of the total Aβ, whereas, APP Florida and 
London, and PS1 M146L and L286V mutations increase the production of Aβx-42 specifically. 
As a consequence, the 5XFAD mice develop plaque deposition as early as 2 months of age, 
which is considered an early time point in comparison to most of the other AD mouse models 
(Oakley et al., 2006). Increased Aβx-42 levels appear to cause enhanced aggregation, early 
deposition and promote the toxicity of Aβ (Barrow and Zagorski, 1991; Iwatsubo et al., 1994; 
Pike et al., 1995).  
In addition to pan Aβ plaques, AβpE3-x plaque deposition was assessed in the 5XFAD 
mice. AβpE3-x is a posttranslationally-modified form of Aβ that starts with a lactam ring at the 
third amino acid position (glutamate). The importance of the AβpE3-x arises from its 
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characteristics: higher aggregation propensity (He and Barrow, 1999; Schilling et al., 2006), 
stronger hydrophobicity (Kuo et al., 1997), and increased toxicity compared with unmodified 
Aβ (Russo et al., 2002). The 5XFAD mice show a steady, age-dependent increase in the area 
covered by AβpE3-x in the hippocampus and the cortex as early as 3 months of age. 
The predominance of AβpE3-x peptides in AD and DS patients and its characteristics 
raised the question about different Aβ isoforms in AD mouse models. In the commonly used 
Tg2576 mouse model, truncated and modified Aβ appears at 16 months of age and comprises 
only 5% of the total Aβ peptides, even at the age of 23 months (Kawarabayashi et al., 2001). 
The authors suggested the scarcity of modified Aβ as one of the reasons underlying the lack of 
neurofibrillary pathology and neuronal loss in Tg2576 brain. AβpE3-x and other modified forms 
of Aβ were absent in another mouse model, the APP23, until 22 months of age. The difference 
in the composition of Aβ pools between AD and the APP23 mouse model might account for 
the different plaque morphology and the high solubility of Aβ peptides in APP23 mice (Kuo 
et al., 2001). On the other hand, a recent study by Schieb et al. (2011) could detect minor 
amounts of AβpE3-x starting at 15 months of age in the brains of APP23 mice brain. Besides, 
the authors reported the presence of AβpE3-x in the brains of 24-month-old APP51 mice, which 
is transgenic for human wild type APP and has an onset of plaque pathology between 12 and 
15 month of age (Schieb et al., 2011). Also, the APP[V717I] London (APP-Ld) mouse model 
was reported recently to develop an age-dependent increase in AβpE3-x starting from 12 months 
of age; however, the ratio of AβpE3-42 to Aβx-42 was relatively low even at 15 months of age 
(Tanghe et al., 2010). The discrepancy in the Aβ isoforms between AD patients and mouse 
models might be due to the short life span of the mice compared to the decades available for 
Aβ post-translational modification in AD.  
The APP/PS1KI mouse model is a double transgenic model with four mutations in 
APP and Presenilin-1 (PS1) (Casas et al., 2004). It develops age-dependent plaque deposition 
and intracellular Aβ accumulation including AβpE3-x as early as 2 month of age (Christensen et 
al., 2008). The area covered with AβpE3 positive plaques increases from less than 1% at 2 
months of age to around 2% at 6 months of age until it covers more than 4.5% of the cortex at 
10 months of age (Wirths et al., 2010a).  
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Despite the value of the AD mouse models in providing Aβ heterogeneity, which is 
relatively similar to that seen in AD, this heterogeneity makes it difficult to distinguish the 
individual toxic peptides from those which might only co-precipitate and could potentially be 
less harmful. Therefore, it was necessary to generate a mouse model that exclusively develops 
N-truncated Aβ. The TBA mouse models express Aβ(Q)3-42 starting with an N-terminal 
glutamine (Q) residue at position three of Aβ, which facilitates the conversion to AβpE3. These 
mice exhibit abundant intraneuronal AβpE3-x associated with neuron loss, striking neurological 
impairment and growth retardation (Wirths et al., 2009; Alexandru et al., 2011). However, the 
severe neurological phenotype and the premature death hinder their use for cognitive or 
longitudinal studies. 
In light of that, choosing the correct AD mouse model harboring Aβ isoforms relevant 
to the purpose of the research is a critical point. This is especially important for studies 
assessing Aβ pathology or testing therapeutic interventions against specific Aβ isoforms. With 
these considerations, the 5XFAD mouse model represents a suitable model to study AβpE3-x. 
The early deposition and the abundance of AβpE3-x in this mouse model facilitate its use to test 
genetic and therapeutic strategies against this Aβ isoform. 
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4.1.7 Conclusions of project I 
Based on the results of the current work 
1. The 5XFAD mouse model was validated on the C57BL/6J genetic background.  
2. 5XFAD mice were shown for the first time to develop motor deficits. 
3. The neurological and motor phenotype in the 5XFAD mice correlated with axonal 
deficits in the spinal cord, which coincided with the presence of intraneuronal Aβ. 
4. Neuron loss in the fifth cortical layer of the 5XFAD mice was quantified and 
confirmed. It was found to coincide with the presence of intraneuronal Aβ. 
5. The reduced spatial alternation previously described in the 5XFAD mouse model was 
recapitulated. 
6. Reduced anxiety was illustrated for the first time in the 5XFAD mice. 
7. The 5XFAD mouse model was verified as valuable model to study the AβpE3-x isoform. 
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4.2 Project II: “Evaluating the role of glutaminyl cyclase and 
pyroglutamate-modified Aβ in AD via the 5XFAD/hQC and 5XFAD/QC-
KO mouse models” 
Beside Aβ peptides starting with aspartate as the first amino acid (Aβ1-x), analysis of 
Aβ peptides isolated from AD and DS deposits revealed several truncated and modified Aβ 
species (Masters et al., 1985b; Roher et al., 1993; Naslund et al., 1994; Saido et al., 1995). 
Among these species, the AβpE3-x peptides represent a major fraction (Saido et al., 1996). The 
conversion of Aβ1-x into AβpE3-x leads to altered biochemical characteristics pointing to 
changes in aggregation, stability (He and Barrow, 1999; Schilling et al., 2006) and toxicity 
(Russo et al., 2002). Compiling findings from in vitro (Cynis et al., 2008a) and in vivo 
(Schilling et al., 2008c) experiments have recently proven that QC enzyme catalyzes the 
formation of AβpE3-x, making it a potential therapeutic target.   
As shown in the previous project, the 5XFAD mouse model represents a suitable 
model to study QC and AβpE3-x due to abundant AβpE3-x formation and the aggressiveness of 
AD pathology. With these considerations, the objective of the current project was to 
investigate, on a genetic basis, the role of QC in an AD mouse model. Therefore, the 
pathological role of QC was studied by generating 5XFAD mice overexpressing hQC 
(5XFAD/hQC mice). More importantly, 5XFAD mice lacking QC (5XFAD/QC-KO mice) 
were generated to analyze the contribution of endogenous QC to AβpE3-x formation and thus 
AD pathology. The resultant mice were analyzed in terms of Aβ pathology and behavioral 
impairments.  
 
4.2.1 The 5XFAD/hQC mouse model  
In order to study the role of QC overexpression in the production of AβpE3-x and thus 
on the pathology of AD, the 5XFAD mice were crossed with hQC mice to generate the 
5XFAD/hQC bigenic mouse model. This model produces ectopic QC expression; however, it 
provides a profound understanding for the pathological consequences of QC increase on AD 
pathology.   
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The choice of the 5XFAD mouse model was supported by the age-dependent analysis 
of AβpE3-x. By 6 months of age, 5XFAD mice show abundant AβpE3-x plaques. On the other 
hand, the higher activity of hQC in comparison to the murine QC (mQC) prompted the use of 
hQC instead of mQC overexpressing mice (Seifert et al., 2009). The activity of QC was 10-40 
times higher in the hQC mice than that in the wildtype controls. hQC mice showed no 
neurological or dysmorphological phenotype. Primary behavioral screening of hQC mice 
(from 3 to 21 months of age) using the SHIRPA protocol did not reveal neurological or 
behavioral abnormalities (Personal communication with Dr. Sigrid Graubner). After crossing 
the 5XFAD with hQC mice, all the resultant genotypes were analyzed at 6 months of age. 
This time point was chosen since by that time the 5XFAD mice harbor significant AβpE3-x 
peptides and behavioral impairments in which modulation of QC activity may result in 
detectable effects. 
To prove the expression of hQC transgene in 5XFAD/hQC and hQC mice, 
immunohistochemistry with an antibody detecting hQC was performed. The staining pattern 
of the transgene followed the Thy-1 promoter expression pattern where it covered different 
brain regions such as the cortex, hippocampus and midbrain regions. In general, QC staining 
showed perikaryal and axonal staining patterns, indicating transportation towards axon 
terminals. Endogenous mQC mRNA was reported to show ubiquitous distribution all over the 
body with the highest expression in the brain in the thalamus and the hippocampus followed 
by the cortex and the cerebellum (Cynis et al., 2008b). 
In order to investigate the effect of QC on AβpE3-x production, it was crucial to assess 
the colocalization of QC with the AβpE3-x precursor, APP. For this purpose, double 
immunofluorescence staining was performed, revealing colocalization between APP and hQC 
in various brain regions, as both transgenes are under the control of Thy-1 promoter. On the 
subcellular level, both APP and hQC showed partial colocalization in the same cellular 
compartments. APP markedly labeled dystrophic neurites around plaques where it showed 
abundant colocalization with hQC. It is noteworthy to mention that APP is transported across 
the axons and accumulates in axonal swellings. Therefore, it is used for the detection of 
axonal pathology in traumatic brain injury (Dolinak and Reichard, 2006) and has been used to 
study axonopathy in the APP/PSKI mice (Wirths et al., 2007). Thus, the colocalization of both 
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proteins provides another indication that hQC is also axonally transported. The current 
findings are consistent with a study by Cynis and colleagues who noted colocalization 
between APP and QC in the Golgi complex of HEK293 cotransfected cells (Cynis et al., 
2008a). The authors suggested that this colocalization functions to catalyze the formation 
AβpE3-x seen in these cells. 
Hartlage-Rubsamen et al. have noted, using immunohistochemistry, that QC 
expression was restricted to neurons whereas no QC signal could be detected in astrocytes 
from wildtype mice (Hartlage-Rubsamen et al., 2009). On the contrary, a recent study 
revealed QC activity in astrocytes culture media which was abolished in cells from QC-KO 
mice (Schilling et al., 2011). Moreover, using reversed phase HPLC coupled with ultraviolet 
detection, an increase in the QC activity in was illustrated in macrophages following 
stimulation with lipopolysaccharides (Chikuma et al., 2004). The discrepancy seen in the 
detection of QC expression may either be due to low QC levels in the basal conditions or due 
to the different sensitivities of the used techniques.  
 
4.2.1.1 hQC overexpression alters pyroglutamate-modified Aβ levels and plaque 
pathology 
The effect of hQC overexpression on Aβ levels and plaque pathology was assessed in 
6-month-old 5XFAD and 5XFAD/hQC mice. Analysis of peptide levels of Aβx-42 using 
ELISA did not reveal any significant differences in the TBS, SDS and Formic levels of Aβx-42. 
As expected, high QC levels in 5XFAD/hQC mice resulted in pronounced effects on AβpE3-42 
peptides. 5XFAD/hQC mice showed significant elevation in all of AβpE3-42 fractions in 
ELISA. The apparent discrepancies between AβpE3-42 and Aβx-42 are likely because Aβx-42 
peptides are 1000 times more abundant than AβpE3-42 in the brain homogenates (μg versus ng/g 
wet weight). Therefore, it is unlikely that the hQC-dependent increase in AβpE3-42 is reflected 
by concomitant increase in Aβx-42 level in a stochiometric pattern. Besides, it is hypothesized 
that AβpE3-42 does not necessarily lead to increased aggregation of Aβx-42, which might be due 
a saturation effect. In line with our findings, incubation of synthetic Aβ3-x with recombinant 
QC resulted in the conversion into AβpE3-x; a reaction that is favored under acidic pH 
conditions and blocked by the presence of a QC inhibitor (Schilling et al., 2004). Similarly, 
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cotransfection of β-TC3 cells with truncated Aβ(E)3-42 and hQC lead to a significant elevation 
in AβpE3-42. Also, cotransfection of HEK293 cells with a truncated APP transgene starting with 
glutamate and an hQC transgene increased AβpE3-42 levels (Cynis et al., 2008a). In both cases, 
addition of QC inhibitor reduced AβpE3-42 levels with no impact on Aβx-42 peptides.  
The consequences of hQC overexpression on the plaque pathology in 5XFAD mice 
were evaluated by quantifying the plaque load in the cortex. Consistent with the ELISA, 
AβpE3-42 plaque load was significantly elevated in 5XFAD/hQC mice in comparison to age-
matched 5XFAD mice. While no significant increase in Aβx-42 levels could be depicted in the 
ELISA, plaque load of pan Aβ was substantially increased in the cortex of 5XFAD/hQC mice. 
AβpE3-x is known to possess higher aggregation propensity, oligomerization and enhanced β-
sheet formation (He and Barrow, 1999). Therefore, it was previously suggested to have a 
seeding effect on plaques (Schilling et al., 2008c). However, the lack of an effect on the SDS 
and formic acid fractions of Aβx-42 in the ELISA contradicts the increased pan Aβ plaque load 
in the cortex of 5XFAD/hQC mice. This might be due to the fact that plaque load 
quantification was limited to the cortex, whereas the ELISA was performed on whole brain 
lysates. Thus, higher total Aβ plaque load in the cortex does not necessarily reflect an overall 
increase in brain Aβ plaques.   
 
4.2.1.2 hQC overexpression worsens the behavior impairments of 5XFAD mice 
The consequences of QC overexpression and the high AβpE3-42 levels in the 
5XFAD/hQC model were studied by following the behavior performance of these mice. As 
described earlier (Chapter 4.1.1), 5XFAD mice display motor impairments in the string 
suspension and the balance beam task starting from 9 months of age. Overexpression of hQC 
in 5XFAD/hQC mice led to an earlier onset of the motor deficits already at 6 months of age. 
Although the 5XFAD mice showed normal alternation behavior in the Y-maze, 5XFAD/hQC 
mice had significantly reduced spatial alternation. In addition, the existing working memory 
deficits demonstrated by the 5XFAD mice in the cross maze were significantly exacerbated in 
the 5XFAD/hQC mice. In both mazes, the reduced alternation was not due to reduced 
locomotor activity since the number of arm entries was not significantly changed.  
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In agreement with the neurological phenotype seen in the 5XFAD/hQC model, the 
TBA2 mouse model expressed tremendous amounts of intraneuronal AβpE3-42 associated with 
loss of Purkinje cells, cerebellar atrophy, growth retardation and premature death. It also 
showed loss of motor coordination and ataxia (Wirths et al., 2009). Two recent transgenic 
models, TBA2.1 and TBA2.2, were developed expressing a similar transgene construct to that 
used in the TBA2 model but with milder pathology. In agreement, these mice displayed 
progressive AβpE3-x deposits in brain regions with neuron loss, impaired LTP, microglial 
activation, and astrocytosis. Along with that, the TBA2.1 mice showed reduced activity and 
body weight, tremor, rigor, abnormal posture in the SHIRPA screen and impaired 
performance in the rotarod test in comparison to wildtype controls. Onset of overt behavioral 
symptoms associated with the peak of AβpE3-x (Alexandru et al., 2011). However, the early, 
severe motor deficits hindered the testing of the TBA mice in cognitive tasks. These data 
clearly illustrate the toxic effect of AβpE3-x in vivo and support the findings in the 
5XFAD/hQC mouse model. On the contrary, a study by Youssef et al. (2008) compared the 
effect of AβpE3-42 and Aβ1-42 after intracerebroventricle injection in wildtype mice. They 
reported that both AβpE3-42 and Aβ1-42 induced similar deficits in the alternation percentage in 
the Y-maze and the delayed memory acquisition in the Y-maze and the Morris water maze 
tests. However, their study investigated the transient consequence of a single injection of 
synthetic peptides. Oppositely, the 5XFAD/hQC mouse model reflects continuous 
overproduction of internally produced and processed peptides. 
Likewise, in vitro experiments proposed AβpE3-40 to be more toxic to neurons and 
astorcytes compared to Aβ1-40 (Russo et al., 2001). Similarly, Aβ mixtures with high AβpE3-42 
contents resulted in significant reduction in the survival levels of neuroblastoma cells 
compared to Aβ1-42 (Piccini et al., 2005).  
Collectively, the 5XFAD/hQC mouse model represents a valuable tool to study the 
pathological effects of QC on the AβpE3-42 production and thus on AD pathology. Despite the 
fact that it is an artificial overexpression model, it is a model which brings the QC enzyme 
together with the Aβ precursor, APP. As a result, levels of AβpE3-42 peptides and AβpE3-x 
plaques were significantly higher in the bigenic mice. This led to a neurological phenotype in 
5XFAD/hQC mice represented by accelerated, significant motor and spatial working memory 
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impairments in comparison to 5XFAD mice, an observation which supports the previously 
suggested toxicity of AβpE3-x in vivo. 
 
4.2.2 The 5XFAD/QC-KO mouse model 
In order to study the effects of endogenous QC on the pathology of AD, 5XFAD/QC-
KO mice were generated. This model represents an invaluable tool to study, on a genetic 
basis, the effects of QC depletion. Ablation of QC resulted in a dramatic drop in enzymatic 
activity in the brain of QC-KO mice. Complete QC ablation did not show effects on mouse 
fertility or weight. Also, QC-KO mice performed indistinguishably from wildtype mice in 
motor tasks, the fear conditioning task, general activity and ingestion behavior. The finding 
that complete QC knockout did not induce significant abnormalities in the mice encouraged 
the use of these mice to study AD or to test therapeutic windows for suppression of QC 
(Schilling et al., 2011). 
 
4.2.2.1 Glutaminyl cyclase ablation reduces Aβ concentration and plaque pathology in 
5XFAD mice 
The impacts of QC knock-out on the Aβ concentrations and plaque pathology in the 
5XFAD/QC-KO mice were evaluated using ELISA and quantitative plaque load analysis. In 
agreement with the ability of hQC overexpression to increase AβpE3-42 levels, knocking out QC 
diminished the TBS soluble AβpE3-42 to undetectable level in the ELISA, with a concomitant 
decrease in the SDS and formic acid soluble AβpE3-42. Surprisingly, this was associated with 
reduction in SDS and formic acid soluble Aβx-42 peptides which might be explained in light of 
the reduced seeding effect of AβpE3-x. In good agreement with the ELISA results, plaque load 
quantifications showed a significant reduction in total Aβ plaque pathology in the cortex. The 
effect on AβpE3-x was more prominent with more than a 70% reduction in the area covered by 
AβpE3-x positive plaques in the cortex of 5XFAD/QC-KO mice.  
The effects of QC reduction, by QC inhibitor, on AD pathology were studied in vivo 
for the first time when Aβ(E)3-40 peptides where injected in rat cortex. Aβ(E)3-40 peptides induced 
an increase in AβpE3-40 concentration and the generation of AβpE3-x positive plaques 24 hours 
after injection utilizing the rat’s endogenous QC. This was significantly decreased via 
79
injection with a QC inhibitor (Schilling et al., 2008b). Utilizing another model system to prove 
the role of QC, transgenic Drosophila flies expressing Aβ(Q)3-42 were treated for 4 weeks with 
a QC inhibitor and showed reduced AβpE3-42 production (Schilling et al., 2008c). Despite the 
difference in the methodology, the effects of the QC inhibitor are principally in agreement 
with the observations from the 5XFAD/QC-KO mice.  
However, AβpE3-42 levels were not completely reduced in 5XFAD/QC-KO mice; 
thereby shedding light on the QC isoenzymes that might be responsible for the formation of 
the AβpE3-x in 5XFAD/QC-KO mice. This is supported by a similar observation in primary 
neurons with homozygous QC-KO. In these cells, the cellular QC-like activity persisted 
whereas the medium activity was diminished (Schilling et al., 2011). In this regard, an 
isoenzyme for QC, isoQC, was recently isolated and characterized in mice and human (Cynis 
et al., 2008a; Stephan et al., 2009). 
To analyze a possible contribution of isoQC to the remaining QC-like activity in the 
5XFAD/QC-KO mice, western blot using an antibody against isoQC was performed. The 
protein levels of isoQC were unchanged in different brain regions between wildtype controls 
and QC-KO mice. This observation demonstrates that the residual AβpE3-x in the 5XFAD/QC-
KO model is possibly mediated by isoQC activity. Recent data by Alexandru et al. (2011) 
showed a similar pattern in which genetic elimination of QC, but not isoQC, resulted in 
around 40% reduction in AβpE3-x level in the TBA2.1 mice. However, the TBA2.1 mice 
express glutamine (instead of the naturally occurring glutamate) at the third position which 
favors spontaneous cyclization into pyroglutamate. Further work is required to understand the 
physiological activity of isoQC especially, since it is likely that QC and isoQC have 
complementary functions. This should be a critical issue for developing drugs that target QC 
activity in different diseases.  
 
4.2.2.2 Glutaminyl cyclase knock-out rescues the spatial working memory impairment in 
5XFAD mice 
The effect of QC ablation on Aβ and the plaque pathology raised the question about its 
impact on the behavior deficits. For this purpose, 6-month-old 5XFAD/QC-KO mice were 
tested in the same behavior tasks as the 5XFAD/hQC mice. The most relevant task in this 
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Fig. 12. Strategies for modulating AβpE3-x 
peptides by genetic modulation of QC, 
treatment with QC-inhibitor or by antibodies 
against AβpE3.-x. 
regard was the cross maze because it was one of the tests in which the 5XFAD mice were 
impaired at 6 months of age, therefore, enabling the detection of possible beneficial effects of 
QC-KO. Consistently, the working memory deficit of the 5XFAD mice was rescued in the 
5XFAD/QC-KO mice, showing an alternation percentage indistinguishable from wildtype 
littermates. Although no changes were detected in other tasks, they are important to 
corroborate that complete QC knockout per se (5XFAD/QC-KO and QC-KO mice) does not 
induce significant behavioral impairments.  
A previous study by Schilling et al. (2008) showed that application of a QC inhibitor 
in vivo had impacts that paralleled the current findings. Oral administration of a QC inhibitor 
in two AD mouse models, the Tg2576 and TASD-41, reduced the concentrations of AβpE3-42, 
Aβx-42 and Aβx-40. Consequently, this reduction was accompanied with alleviation in the plaque 
density and gliosis in addition to improvements in contextual fear memory and spatial 
memory. Notably, similar to our findings, QC inhibitor did not reduce TBS soluble Aβx-42 and 
Aβx-40 levels, ruling out an effect on Aβ production.  
Based on what is mentioned above, the 5XFAD/QC-KO mouse model is a valuable 
model for studying the endogenous contribution of QC to the pathology of AD. Complete 
elimination of QC reduced AβpE3-42 and Aβx-42 concentrations, alleviated the plaque pathology 
and improved the memory impairment in an aggressive AD mouse model.  
In addition to what is mentioned above, 
I contributed to a recent study by our group in 
which a novel monoclonal antibody (9D5) 
against low molecular weight AβpE3-x oligomers 
was generated (Wirths et al., 2010b). The 
toxicity of AβpE3-42 peptides on neuroblastoma 
cells was completely abolished by adding the 
9D5 antibody to the media. 9D5 did not have 
any effect when applied with Aβ1-42. Also, 
levels of AβpE3-42 oligomers were significantly 
reduced in the plasma of AD patients by 46% as 
compared to healthy controls. Over the past 
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decade, immunotherapy gained increasing interest in the field of AD. Thus, immunotherapy 
against AβpE3-x represents an interesting concept as well. In terms of therapeutic potential, 
passive immunization with 9D5 antibody in 4.5-month-old 5XFAD mice for 1.5 months was 
capable of reducing pan Aβ plaque load and AβpE3-x levels, and normalizing the anxiety 
changes seen at 6 months of age. Based on that, low molecular AβpE3-x oligomers represent a 
therapeutically and diagnostically effective target. These data, together with the findings from 
the 5XFAD/QC-KO model and QC-inhibitor studies, suggest that reduction of AβpE3-x levels 
as a beneficial approach for treating AD (Fig. 12).  
In summary, findings from 5XFAD/hQC and 5XFAD/QC-KO mice clearly 
demonstrate on a genetic basis the major role played by QC in AD pathology by its direct 








4.2.3 Conclusions of project II  
Based on the results of the current work 
1. The role of QC in the pathology of AD was elucidated for the first time using genetic tools  
    in an aggressive AD mouse model with abundant AβpE3-x formation. 
2. Ectopic expression of hQC in the 5XFAD/hQC model showed colocalization with  
    APP and led to increased formation of AβpE3-42. 
3. The increased AβpE3-42 concentration aggravated the severity of the 5XFAD neurological    
    phenotype. 
4. Genetic elimination of endogenous QC in the 5XFAD/QC-KO reduced AβpE3-42 production  
    and thus plaque pathology. 
5. The residual AβpE3-42 in the 5XFAD/QC-KO suggests a role for isoQC enzymes. 



















5. Summary  
AD mouse models contributed widely to our understanding of the pathophysiology of 
AD and represent invaluable tools in testing potential therapeutic interventions. In the present 
study, age-dependent characterization of the neuropathological and behavioral hallmarks of 
the 5XFAD mouse model was performed, demonstrating that the 5XFAD mouse model 
develops a variety of AD neuropathological and behavioral hallmarks. It was shown for the 
first time that the 5XFAD mice develop neurological and motor phenotypes, which coincide 
with spinal cord pathology such axonopathy and intraneuronal Aβ. One of the most important 
characteristics originally reported in the 5XFAD mouse model is the neuron loss; however, 
this was never appropriately quantified. Using designed-based stereology, it was shown that 
the 5XFAD mice develop significant selective neuron loss in the fifth cortical of the frontal 
cortex which correlates with the accumulation of intraneuronal Aβ peptides. The 5XFAD 
mouse model develops early age-dependent alterations in anxiety levels and impaired spatial 
working memory starting from 6 months of age. Employing a variety of Aβ specific 
antibodies, abundant intraneuronal Aβ and extracellular plaque deposition was noted and 
showed age-dependent alterations. Altogether, the simultaneous occurrence of age-dependent 
neuropathological and the behavioral changes present the 5XFAD mouse model as an 
invaluable model to study AD. More importantly, the cosegregation of the mutations in the 
5XFAD facilitates its use to generate bigenic mouse models. 
AβpE3-x is a modified form of Aβ which is particularly interesting due to its 
predominance in AD brains and its high pathogenicity. The above mentioned considerations, 
in addition to the early deposition and the abundance of AβpE3-x in the 5XFAD mouse model, 
prompted its use to test genetic strategies for modulating this Aβ isoform. Several in vitro and 
in vivo lines of evidence suggested that QC enzyme is responsible for the formation of AβpE3-x. 
In order to study the pathological contribution of QC to the pathology of AD, 5XFAD mice 
were crossed with hQC mice to generate a bigenic model of AD with QC overexpression, the 
5XFAD/hQC model. The 5XFAD/hQC mouse model brought together QC and the Aβ 
precursor leading to higher AβpE3-x levels. As a consequence, the 5XFAD/hQC mice exhibited 
higher AβpE3-x plaque pathology and accelerated motor and spatial working memory 
impairments in comparison to the 5XFAD mice. More importantly, the endogenous 
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contribution of QC to AD pathology was studied by generating the 5XFAD/QC-KO bigenic 
mouse model. Complete depletion of QC reduced AβpE3-42 and Aβx-42 concentrations, 
alleviated the plaque pathology and improved the memory impairment in the 5XFAD/QC-KO 
mouse model. Taken together, the outcome of this work clearly indicates the pivotal role of 
QC in AD pathology. 
In summary, the aim of this thesis was to perform an age-dependent characterization of 
the 5XFAD mouse model and to verify its use in studying strategies that modulate AβpE3-x and 
thus AD pathology. Based on that, data from the 5XFAD/hQC and the 5XFAD/QC-KO mice 
clearly demonstrate that QC is an essential enzyme modulating AβpE3-42 levels in vivo and 
proves on a genetic basis the concept that reduction of QC activity is an interesting new 
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